```
-> b reg
FILE 'REGISTRY' ENTERED AT 17:47:48 ON 21 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 OCT 2009  HIGHEST RN 1189242-76-9
DICTIONARY FILE UPDATES:  20 OCT 2009  HIGHEST RN 1189242-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

-> d que sta 16
L1  (    394386)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC5 OR NCNC3-NC5
                   OR NC2NC2-NC5 OR N2CNC2-NC5)/ES
L2  (      8932)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC6 OR NC5-NCNC4
                   OR NC5-NC2NC3 OR NC5-N2CNC3)/ES
L3       403278 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (L1 OR L2)
L4             STR

             6
             G2            Hy @7      Ak~Hy       Cb~Hy
             |                        @8  9       @10 11
Cy~G1~N~~C~~G3
 1   2   3   4   5


REP G1=(1-3) C
VAR G2=O/S
VAR G3=7/8/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M6-X9 C  M2-X4 N  AT   7
ECOUNT  IS M6-X9 C  M2-X4 N  AT   9
ECOUNT  IS M6-X9 C  M2-X4 N  AT  11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L6        12143 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED  118234 ITERATIONS                      12143 ANSWERS
SEARCH TIME: 00.00.04



-> d que sta l9
L1  (    394386)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC5 OR NCNC3-NC5
                   OR NC2NC2-NC5 OR N2CNC2-NC5)/ES
L2  (      8932)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC6 OR NC5-NCNC4
                   OR NC5-NC2NC3 OR NC5-N2CNC3)/ES
L3       403278 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (L1 OR L2)
L4             STR
```

REP G1=(1-3) C
VAR G2=O/S
VAR G3=//8/10
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M6-X9 C M2-X4 N AT 7
ECOUNT IS M6-X9 C M2-X4 N AT 9
ECOUNT IS M6-X9 C M2-X4 N AT 11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L6 12143 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7 STR



REP G1=(1-3) C
VAR G2=O/S
VAR G3=13/12/17/8/10
REP G4=(0-1) C
VAR G5=C/N
VAR G6=13/12/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L9 1594 SEA FILE=REGISTRY SUB=L6 SSS FUL L7

100.0% PROCESSED 12143 ITERATIONS 1594 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l17
L1 (394386)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (NC5-NC5 OR NCNC3-NC5
OR NC2NC2-NC5 OR N2CNC2-NC5)/ES
L2 (8932)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (NC5-NC6 OR NC5-NCNC4
OR NC5-NC2NC3 OR NC5-N2CNC3)/ES
L3 403278 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (L1 OR L2)
L4 STR

REP G1=(1-3) C
VAR G2=O/S
VAR G3=7/8/10

```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M6-X9 C  M2-X4 N  AT   7
ECOUNT  IS M6-X9 C  M2-X4 N  AT   9
ECOUNT  IS M6-X9 C  M2-X4 N  AT  11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L6          12143 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7                STR
```

```
REP G1=(1-3) C
VAR G2=O/S
VAR G3=13/12/17/8/10
REP G4=(0-1) C
VAR G5=C/N
VAR G6=13/12/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  21

STEREO ATTRIBUTES: NONE
L9          1594 SEA FILE=REGISTRY SUB=L6 SSS FUL L7
L15               STR
```



```
REP G1=(1-3) C
VAR G2=O/S
VAR G3=13/12/17/8/10
REP G4=(0-1) C
VAR G5=C/N
VAR G6=13/12/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L17          932 SEA FILE=REGISTRY SUB=L9 SSS FUL L15

100.0% PROCESSED    1594 ITERATIONS                          932 ANSWERS
SEARCH TIME: 00.00.01


-> b zcap
```

FILE 'ZCAPLUS' ENTERED AT 17:48:00 ON 21 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Oct 2009 VOL 151 ISS 17
FILE LAST UPDATED: 20 Oct 2009 (20091020/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr 120 tot

```
L20  ANSWER 1 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2007:454282  ZCAPLUS
DN   146:462291
TI   Preparation of heterocyclyl acrylamide compounds as FabI inhibitors
IN   Manning, David Douglas; Decornez, Helene Yvonne; Surman, Matthew David;
     Martin, Fernando J. L.; Ramnauth, Jailall; Toro, Andras; Berman, Judd M.;
     Sampson, Peter; Pauls, Henry; Sargent, Bruce Jeremy
PA   Affinium Pharmaceuticals, Inc., Can.
SO   Can. Pat. Appl., 232 pp.
     CODEN: CPXXEB
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
PI   CA----2568914        A1    20051204   2005CA-002568914       20050606
     WO--2007053131       A2    20070510   2005WO-US0019805       20050606
     WO--2007053131       A3    20070802
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
             KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     EP-----1828167       A2    20070905   2005EP-000858503       20050606
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, MK, YU
     JP--2008505194       T     20080221   2007JP-000543017       20050606
     KR--2008016517       A     20080221   2007KR-000700169       20070103
PRAI 2004US-00576945P     P     20040604
     2005WO-US0019805     W     20050606
OS   MARPAT 146:462291
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

AB   Title compds. I [A = monocyclic ring containing 0-2 heteroatoms, bicyclic ring
     containing 0-4 heteroatoms, tricyclic ring containing heteroatoms containing 0-6
     heteroatoms (wherein the rings are independently aliphatic, aromatic,
     heteroaryl, etc.), the heteroatoms are selected from N, S and O and the
     rings are optionally substituted with alkyl, CN, OCF3, etc.); R = Q1,
     etc.; R1 = H, alkyl, aryl, R2 = H, alkyl, aryl; R1 and R2 may combine to
     form a fused ring.; R3 = H, alkyl, aryl; R2 and R3 combine to form a
     spirocyclic ring.; R5 = H, alkyl, aryl] or their pharmaceutically
     acceptable salts were prepared. For example, Pd(OAc)2 catalyzed coupling
     reaction of N-(2-ethoxy-3-trifluoromethoxybenzyl)-N-methylacrylamide,
     e.g., prepared from 2-trifluoromethoxyphenol in 4 steps, with
     7-bromo-3,3-dimethyl-1,3,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-2-one
     followed by treatment with HCl afforded compound II hydrochloride.  In E.
     coli FabI enzyme inhibition assays, the invention compds. showed the IC50
     values ranging from 0.05 μM to 100 μM.
IT   709652-79-9P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of heterocyclyl acrylamide compds. as FabI inhibitors)
IT   709652-77-7P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of heterocyclyl acrylamide compds. as FabI inhibitors)
```

```
L20  ANSWER 1 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
IT   709652-79-9P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (preparation of heterocyclyl acrylamide compds. as FabI inhibitors)
RN   709652-79-9  ZCAPLUS
CN   2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-
     tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)-
     (CA INDEX NAME)

Double bond geometry as shown
```

```
OSC.G    1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
```

```
L20  ANSWER 2 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2006:636869  ZCAPLUS
DN   145:103734
TI   Compositions comprising multiple antibiotic agents including a FabI
     inhibitor, methods of using the same, and preparation of the heterocycle
     FabI inhibitors
IN   Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PA   Affinium Pharmaceuticals, Inc., Can.
SO   U.S. Pat. Appl. Publ., 192 pp., which which
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
PI   US-20060142265       A1    20060629   2005US-000231298       20050919
     WO--2004082586       A2    20040930   2004WO-IB0001261       20040317
     WO--2004082586       A3    20041223
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
PRAI 2003US-00455189P     P     20030317
     2003US-00476970P     P     20030609
     2003US-00488379P     P     20030718
     2004WO-IB0001261     A2    20040317
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 145:103734
GI
```

II

```
AB   The invention is directed to antibacterial compns. comprising an NADH (or
     NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI,
     previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2
     (I) and at least one other antibiotic/antibacterial agent [L = alkyl,
     alkenyl, or cycloalkyl which may be substituted by one or more R1, A =
     (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of
     12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O, R1 = H,
     cyclo/alkyl, alk/aryl, R2 = heterocyclyl, a = 0-4, Y1 = -(CH2)n-CO-NR4R5,
     R4 = water solubilizing group, R5 = H, cyclo/alkyl, n = 0-4].  The
     antibacterial composition exhibits a synergistic antibacterial effect compared
     to its individual components.  Thus, bromination of
     (S)-2-methyl-1,2,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-3-one (preparation
     given), coupling of the bromide with
     N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]acrylamide, and acidulation of
     the free base (no data) with TFA gave pyridodiazepine II•TFA.
     Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory
     concentration) < 0.125 μg/mL, and an IC50 < 10 nM.
IT   709652-36-8P  (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-
     yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
     yl]ethanoic acid   709652-79-9P
     (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
     7-yl)-N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]-2-propenamide
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
```

```
L20  ANSWER 2 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (bactericide; compns. comprising multiple antibiotic agents and prepn.
        of heterocycle FabI inhibitor)
IT   709650-75-9P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-
     propenamide monohydrochloride   709650-79-3P,
     (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
     7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide
     monohydrochloride   709650-84-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(naphthalen-2-yl)methyl]-2-propenamide
     monohydrochloride   709650-86-2P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(naphthalen-1-yl)methyl]-2-propenamide
     monohydrochloride   709650-87-3P,
     (E)-N-(4-Acetylaminobenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709650-91-9P
     709650-92-0P, (E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(7-
     oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide
     709650-95-3P, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(7-
     oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide
     709650-98-6P, (E)-N-(2,3-Dimethylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-
     tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide   709651-00-3P,
     (E)-N-(4-Isopropylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709651-03-6P,
     (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709651-07-0P,
     (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-09-2P, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-
     yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-11-6P, (E)-N-(3,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-
     oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-12-7P,
     (E)-N-[2-(1H-Indol-3-yl)ethyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-13-8P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-(2,4,5-trimethoxybenzyl)-2-propenamide
     monohydrochloride   709651-15-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(phenanthren-9-yl)methyl]-2-propenamide
     monohydrochloride   709651-17-2P,
     (E)-N-[(Acenaphthen-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-18-3P,
     (E)-N-(4-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-19-4P     709651-20-7P,
     (E)-N-(2,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-22-9P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(quinolin-4-yl)methyl]-2-propenamide
     monohydrochloride   709651-25-2P,
     (E)-N-(4-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-27-4P,
     (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-28-5P,
     (E)-N-(3,4-Dimethylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-29-6P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-IH-
     pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,6-trimethylbenzyl)-2-propenamide
     monohydrochloride   709651-30-9P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-(2,4,5-trimethylbenzyl)-2-propenamide
     monohydrochloride   709651-31-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(quinolin-3-yl)methyl]-2-propenamide
     monohydrochloride   709651-32-1P,
     (E)-N-(3,4-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
```

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
709651-33-2P, (E)-N-[(Benzofuran-2-yl)methyl]-N-methyl-3-(4-methyl-
2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-34-3P**,
(E)-N-Methyl-N-(2-methylnaphthalen-1-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-35-4P**,
(E)-N-[(Biphenyl-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-36-5P**,
(E)-N-[(Biphenyl-3-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-37-6P**,
(E)-N-(2-Ethoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-38-7P**,
(E)-N-(2-Ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
709651-40-1P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,3,4-trimethoxybenzyl)-2-propenamide
monohydrochloride **709651-41-2P**,
(E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]-N-methyl-3-(4-methyl-2-
oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-42-3P**,
(E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
709651-43-4P, (E)-N-(3-Ethoxy-2-methoxybenzyl)-N-methyl-3-(4-
methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
propenamide monohydrochloride **709651-44-5P**,
(E)-N-(2-Ethoxy-3-methylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-45-6P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl)-N-[(quinolin-5-yl)methyl]-2-propenamide
monohydrochloride **709651-46-7P**,
(E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-47-8P**,
(E)-N-(3-Methoxy-2-isopropoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-48-9P**,
(E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-49-0P**,
(E)-N-(3-Chloro-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-50-3P**,
(E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-51-4P**,
(E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-5-yl)methyl]-N-methyl-3-(4-methyl-2-
oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-52-5P**,
(E)-N-(4,5-Dimethylnaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-
2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-53-6P**,
(E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-56-9P**,
(E)-N-Benzyl-N-methyl-3-(7-oxo-5,6,7,9-tetrahydro-[1,9]naphthyridin-3-yl)-
2-propenamide **709651-57-0P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-58-1P**,
(E)-[7-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-
1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanoic acid ethyl
ester monohydrochloride **709651-59-2P**,
(E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
709651-60-5P, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(4-

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
propenamide monohydrochloride **709651-61-6P**,
(E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-62-7P**,
(R)-(+)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide
monohydrochloride **709651-63-8P**,
(S)-(-)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide
monohydrochloride **709651-64-9P**,
(E)-N-[(Benzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-65-0P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl)-N-(3-trifluoromethylbenzyl)-2-propenamide
monohydrochloride **709651-66-1P**,
(E)-N-(2-Chlorobenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
709651-67-2P, (E)-N-Methyl-N-(4-methylbenzyl)-3-(4-methyl-2-oxo-
2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-70-7P**,
(E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-
propenamide monohydrochloride **709651-71-8P**
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-74-1P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(morpholin-
4-yl)ethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-
propenamide monohydrochloride **709651-75-2P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(4-
methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
709651-76-3P, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-
yl)methyl]-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-
pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
709651-77-4P, (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[4-[2-(4-
methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
709651-80-9P, (E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-(4-
methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
propenamide monohydrochloride **709651-81-0P**,
(E)-N-(4-Chloronaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-82-1P**,
(E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[4-[3-(morpholin-4-
yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-
propenamide monohydrochloride **709651-83-2P**
(E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[4-[3-(morpholin-4-
yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-
propenamide monohydrochloride **709651-84-3P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[3-(4-
methylpiperazin-1-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
709651-85-4P, (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[4-
[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
709651-86-5P, (E)-N-[(3-Chlorobenzo[b]thiophen-2-yl)methyl]-N-
methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
7-yl)-2-propenamide monohydrochloride **709651-87-6P**,
(E)-N-[(5-Chloro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-
2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride **709651-88-7P** **709651-89-8P**,
(E)-N-[(5-Fluoro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-
methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
propenamide monohydrochloride **709651-90-1P**,
(E)-N-[(5-Chloro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-
methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
propenamide monohydrochloride **709651-93-4P**,

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709651-94-5P, (E)-7-[2-[Methyl[(1-methyl-1H-indol-3-
yl)methyl]carbamoyl]vinyl]-2-oxo-1,2,3,5-tetrahydropyrido[2,3-
e][1,4]diazepine-4-carboxylic acid benzyl ester **709651-95-6P**,
(E)-3-(2,4-Dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-N-methyl-N-
[(1-methyl-1H-indol-3-yl)methyl]-2-propenamide **709652-14-2P**
709652-15-3P, (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-(7-
oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide
monohydrochloride **709652-16-4P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
[1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride
709652-30-2P, (E)-3-[3-(2-Dimethylaminoethyl)-2-oxo-1,2,3,4-
tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(1-methyl-1H-indol-2-
yl)methyl]-2-propenamide **709652-31-3P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(morpholin-4-
yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-32-4P**,
(E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-[3-[2-(morpholin-4-
yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-34-6P**,
(E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-
oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
monohydrochloride **709652-35-7P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(morpholin-
4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-38-0P**,
(E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-
1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid sodium salt
709652-39-1P, (E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-
yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
yl]ethanoic acid sodium salt **709652-41-5P**,
(E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-
1-yl)-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-42-6P**,
(E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-
methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-
d]pyrimidin-6-yl]-2-propenamide monohydrochloride **709652-46-0P**
, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-
methylpiperazin-1-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-
6-yl]-2-propenamide monohydrochloride **709652-51-7P**
709652-55-1P (E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-[3-[2-
(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-
yl]-2-propenamide monohydrochloride **709652-56-2P**,
(E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-
yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-57-3P**
709652-58-4P (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[3-
[2-(morpholin-4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-
yl]-2-propenamide monohydrochloride **709652-59-5P**,
(E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[3-[2-(morpholin-4-
yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-60-8P**,
(E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-
oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
monohydrochloride **709652-61-9P**
(E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-[3-[2-(morpholin-4-
yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
propenamide monohydrochloride **709652-62-0P**
(E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
[1,8]naphthyridin-3-yl)-2-propenamide **709652-65-3P**,
(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
e][1,4]diazepin-7-yl)-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-propenamide
709652-66-4P (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-
[1,8]naphthyridin-3-yl)-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-
propenamide **709652-71-1P**,
(E)-N-(1H-Indol-5-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **709652-72-2P**
(E)-N-Methyl-N-(1-methylindol-5-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-73-3P (E)-N-(1H-Indol-7-ylmethyl)-N-methyl-3-(4-methyl-2-
oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-74-4P
(E)-N-Methyl-N-(1-methylindol-7-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-

L20 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-75-5P, (E)-N-(1H-Indol-6-ylmethyl)-N-methyl-3-(4-methyl-2-
oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-77-7P **709652-80-2P**,
(E)-N-Methyl-N-[(3-methyl-1H-inden-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-
tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
monohydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(bactericide; compns. comprising multiple antibiotic agents and prepn.
of heterocycle FabI inhibitor)

IT **709651-73-0**, (E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-
1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-
yl)methyl]-2-propenamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. comprising multiple antibiotic agents and preparation of
heterocycle FabI inhibitor)

IT **709652-47-1P**
RL. SPN (Synthetic preparation); PREP (Preparation)
(compns. comprising multiple antibiotic agents and preparation of
heterocycle FabI inhibitor)

IT **709650-77-1P**, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-
propenamide **709650-81-7P**,
(E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide
709651-72-9P, (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-
oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
709652-37-9P, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-
yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
yl]ethanoic acid ethyl ester **709652-43-7P**,
(E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-
oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid
709652-44-8P, (E)-3-[3-(2,2-Dimethoxyethyl)-2-oxo-1,2,3,4-
tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(3-
methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide **709652-45-9P**
, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[2-oxo-3-(2-
oxoethyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; compns. comprising multiple antibiotic agents and preparation
of heterocycle FabI inhibitor)

IT **709652-36-8P**, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-
yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
yl]ethanoic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(bactericide; compns. comprising multiple antibiotic agents and preparation
of heterocycle FabI inhibitor)

RN 709652-36-8 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid,
1,4-dihydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-2-yl)methyl]amino]-3-oxo-
1-propen-1-yl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)



```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2004:799437  ZCAPLUS
DN   141:314353
TI   Compositions comprising multiple antibiotic agents including a FabI
     inhibitor, methods of using the same, and preparation of the heterocycle
     FabI inhibitors
IN   Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PA   Affinium Pharmaceuticals, Inc., Can.
SO   PCT Int. Appl., 311 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
PI   WO--2004082586       A2    20040930   2004WO-IB0001261       20040317
     WO--2004082586       A3    20041223
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     CA-----2519429       A1    20040930   2004CA-002519429       20040317
     EP-----1608377       A2    20051228   2004EP-000721257       20040317
     EP-----1608377       B1    20081001
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
     JP--2006523207       T     20061012   2006JP-000506526       20040317
     AT------409485       T     20081015   2004AT-000721257       20040317
     US-20060142265       A1    20060629   2005US-000231299       20050919
PRAI 2003US-00455189P     P     20030317
     2003US-00476970P     P     20030609
     2003US-00488379P     P     20030718
     2004WO-IB0001261     W     20040317
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 141:314353
GI
```

I

```
AB   The invention is directed to antibacterial compns. comprising an NADH (or
     NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI,
     previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2
     (I) and at least one other antibiotic/antibacterial agent [L = alkyl,
     alkenyl, or cycloalkyl which may be substituted by one or more R1; A =
     (un)substituted bicyclic heteroaryl of 9-12 atoms or a tricyclic ring of
     12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 =
     cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5;
     R4 = water solubilizing group, R5 = H, cyclo/alkyl; n = 0-4].  The
     antibacterial composition exhibits a synergistic antibacterial effect compared
     to its individual components.  Thus, reacting
     7-Bromo-3,3-dimethyl-1,3,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-2-one
     (preparation given) with N-Methyl-N-[(3-methylbenzo[b]thiophen-2-
     yl)methyl]acrylamide (preparation given), followed by acidulation gave
     diazepinone salt II•HCl.  Selected I inhibited FabI with a Ki < 1 nM,
     an MIC (minimal inhibitory concentration) < 0.125 µg/mL, and an IC50 < 10 nM.
```

```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
IT   709652-36-8P, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-
     yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
     yl]ethanoic acid
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (bactericide; compns. comprising multiple antibiotic agents and preparation
        of heterocycle FabI inhibitor)
IT   709650-75-9P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-
     propenamide monohydrochloride   709650-79-3P,
     (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
     7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide
     monohydrochloride   709650-84-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(naphthalen-2-yl)methyl]-2-propenamide
     monohydrochloride   709650-86-2P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(naphthalen-1-yl)methyl]-2-propenamide
     monohydrochloride   709650-87-3P,
     (E)-N-(4-Acetylaminobenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709650-91-9P,
     (E)-N-(4-Methylsulfonylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709650-92-0P,
     (E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-
     tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide   709650-95-3P,
     (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709650-98-6P,
     (E)-N-(2,3-Dimethylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709651-00-3P,
     (E)-N-(4-Isopropylbenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709651-03-6P,
     (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709651-07-0P,
     (E)-N-[(Indan-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-09-2P, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-
     yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-11-6P, (E)-N-(3,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-
     oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-12-7P,
     (E)-N-[2-(1H-Indol-3-yl)ethyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-13-8P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-(2,4,5-trimethoxybenzyl)-2-propenamide
     monohydrochloride   709651-15-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(phenanthren-9-yl)methyl]-2-propenamide
     monohydrochloride   709651-17-2P,
     (E)-N-[(Acenaphthen-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-18-3P,
     (E)-N-(4-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-19-4P,
     (E)-N-[(Benzodioxol-5-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-20-7P,
     (E)-N-(2,5-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-22-9P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(quinolin-4-yl)methyl]-2-propenamide
     monohydrochloride   709651-25-2P,
     (E)-N-(4-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-27-4P,
     (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
```

```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     monohydrochloride   709651-28-5P,
     (E)-N-(3,4-Dimethylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-29-6P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,4,6-trimethylbenzyl)-2-propenamide
     monohydrochloride   709651-30-9P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-(2,4,5-trimethylbenzyl)-2-propenamide
     monohydrochloride   709651-31-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(quinolin-3-yl)methyl]-2-propenamide
     monohydrochloride   709651-32-1P,
     (E)-N-(3,4-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-33-2P, (E)-N-[(Benzofuran-2-yl)methyl]-N-methyl-3-(4-methyl-
     2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-34-3P,
     (E)-N-Methyl-N-(2-methylnaphthalen-1-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-35-4P,
     (E)-N-[(Biphenyl-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-36-5P,
     (E)-N-[(Biphenyl-3-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-37-6P,
     (E)-N-(2-Ethoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-38-7P,
     (E)-N-(2-Ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-40-1P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl)-N-(2,3,4-trimethoxybenzyl)-2-propenamide
     monohydrochloride   709651-41-2P,
     (E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]-N-methyl-3-(4-methyl-2-
     oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-42-3P,
     (E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-43-4P, (E)-N-(3-Ethoxy-2-methoxybenzyl)-N-methyl-3-(4-
     methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
     propenamide monohydrochloride   709651-44-5P,
     (E)-N-(2-Ethoxy-3-methylbenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-45-6P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(quinolin-5-yl)methyl]-2-propenamide
     monohydrochloride   709651-46-7P,
     (E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-47-8P,
     (E)-N-(3-Methoxy-2-isopropoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-48-9P,
     (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-49-0P,
     (E)-N-(3-Chloro-2-methoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-50-3P,
     (E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-51-4P,
     (E)-N-[(2,3-Dihydrobenzo[1,4]dioxin-5-yl)methyl]-N-methyl-3-(4-methyl-2-
     oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-52-5P,
     (E)-N-(4,5-Dimethylnaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-
     2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-53-6P,
     (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-56-9P,
     (E)-N-Benzyl-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-
     2-propenamide   709651-57-0P,
```

```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-58-1P,
     (E)-[7-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-
     1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanoic acid ethyl
     ester monohydrochloride   709651-59-2P,
     (E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-60-5P, (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-(4-
     methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
     propenamide monohydrochloride   709651-61-6P,
     (E)-N-(2-Methoxynaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-62-7P,
     (R)-(+)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide
     monohydrochloride   709651-63-8P,
     (S)-(-)-(E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[1-(naphthalen-1-yl)ethyl]-2-propenamide
     monohydrochloride   709651-64-9P,
     (E)-N-[(Benzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-65-0P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-(3-trifluoromethylbenzyl)-2-propenamide
     monohydrochloride   709651-66-1P,
     (E)-N-(2-Chlorobenzyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide monohydrochloride
     709651-67-2P, (E)-N-Methyl-N-(4-methylbenzyl)-3-(4-methyl-2-oxo-
     2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-70-7P,
     (E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-2-
     propenamide monohydrochloride   709651-71-8P,
     (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-74-1P,
     (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(morpholin-
     4-yl)ethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-
     propenamide monohydrochloride   709651-75-2P,
     (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[2-(4-
     methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
     709651-76-3P, (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-
     yl)methyl]-3-[4-[3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-
     pyrido[2,3-e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
     709651-77-4P, (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[4-[2-(4-
     methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
     709651-80-9P, (E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-(4-
     methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
     propenamide monohydrochloride   709651-81-0P,
     (E)-N-(4-Chloronaphthalen-1-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-82-1P,
     (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[4-[3-(morpholin-4-
     yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-
     propenamide monohydrochloride   709651-83-2P,
     (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[4-[3-(morpholin-4-
     yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl]-2-
     propenamide monohydrochloride   709651-84-3P,
     (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[4-[3-(4-
     methylpiperazin-1-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
     709651-85-4P, (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[4-
     [3-(morpholin-4-yl)propyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl]-2-propenamide monohydrochloride
     709651-86-5P, (E)-N-[(3-Chlorobenzo[b]thiophen-2-yl)methyl]-N-
     methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
     7-yl)-2-propenamide monohydrochloride   709651-87-6P,
     (E)-N-[(5-Chloro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-
     2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-88-7P,
     (E)-N-[(1,7-Dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(4-methyl-2-oxo-
```

```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride   709651-89-8P,
     (E)-N-[(5-Fluoro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-
     methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
     propenamide monohydrochloride   709651-90-1P,
     (E)-N-[(5-Chloro-3-methylbenzo[b]thiophen-2-yl)methyl]-N-methyl-3-(4-
     methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
     propenamide monohydrochloride   709651-93-4P,
     (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     709651-94-5P, (E)-7-[2-[Methyl[(1-methyl-1H-indol-3-
     yl)methyl]carbamoyl]vinyl]-2-oxo-1,2,3,5-tetrahydropyrido[2,3-
     e][1,4]diazepine-4-carboxylic acid benzyl ester   709651-95-6P,
     (E)-3-(2,4-Dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)-N-methyl-N-
     [(1-methyl-1H-indol-3-yl)methyl]-2-propenamide   709652-14-2P,
     (E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride
     709652-15-3P, (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-(7-
     oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-2-propenamide
     monohydrochloride   709652-16-4P,
     (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide monohydrochloride
     709652-30-2P, (E)-3-[3-(2-Dimethylaminoethyl)-2-oxo-1,2,3,4-
     tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(1-methyl-1H-indol-2-
     yl)methyl]-2-propenamide   709652-31-3P,
     (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(morpholin-4-
     yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-32-4P,
     (E)-N-Methyl-N-(4-methylnaphthalen-1-ylmethyl)-3-[3-[2-(morpholin-4-
     yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-34-6P,
     (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-
     oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
     monohydrochloride   709652-35-7P,
     (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(morpholin-
     4-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-38-0P,
     (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-yl)methyl]carbamoyl]vinyl]-2-oxo-
     1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid sodium salt
     709652-39-1P, (E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-
     yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
     yl]ethanoic acid sodium salt   709652-41-5P,
     (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-[3-[2-(4-methylpiperazin-
     1-yl)-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-42-6P,
     (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-
     methylpiperazin-1-yl)-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-
     d]pyrimidin-6-yl]-2-propenamide monohydrochloride   709652-46-0P
     , (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[3-[2-(4-
     methylpiperazin-1-yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-
     6-yl]-2-propenamide monohydrochloride   709652-51-7P,
     (E)-N-(2-Ethoxy-3-methoxybenzyl)-N-methyl-3-[3-[3-(morpholin-4-yl)propyl]-
     2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
     monohydrochloride   709652-55-1P,
     (E)-N-(2,3-Diethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-oxo-
     1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
     monohydrochloride   709652-56-2P,
     (E)-N-(2-Isopropoxy-3-methoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-
     yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-57-3P,
     (E)-N-(3-Methoxy-2-propoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-
     2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
     monohydrochloride   709652-58-4P,
     (E)-N-Methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-[3-[2-(morpholin-4-
     yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-59-5P,
     (E)-N-Methyl-N-(2-methylbenzofuran-3-ylmethyl)-3-[3-[2-(morpholin-4-
     yl)ethyl]-2-oxo-1,2,3,A-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-60-8P,
     (E)-N-(3-Chloro-2-ethoxybenzyl)-N-methyl-3-[3-[2-(morpholin-4-yl)ethyl]-2-
```

```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
     monohydrochloride   709652-61-9P,
     (E)-N-(4-Fluoronaphthalen-1-ylmethyl)-N-methyl-3-[3-[2-(morpholin-4-
     yl)ethyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-
     propenamide monohydrochloride   709652-62-0P
, (E)-N-(2,3-Dimethoxybenzyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-2-propenamide   709652-65-3P,
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-propenamide
     709652-66-4P, (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-
     [1,8]naphthyridin-3-yl)-N-[(thieno[3,2-c]pyridin-2-yl)methyl]-2-
     propenamide   709652-71-1P,
     (E)-N-(1H-Indol-5-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide   709652-72-2P
     , (E)-N-Methyl-N-(1-methylindol-5-ylmethyl)-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     709652-73-3P, (E)-N-(1H-Indol-7-ylmethyl)-N-methyl-3-(4-methyl-2-
     oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     709652-74-4P, (E)-N-Methyl-N-(1-methylindol-7-ylmethyl)-3-(4-
     methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-
     propenamide   709652-75-5P,
     (E)-N-(1H-Indol-6-ylmethyl)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide   709652-79-9P
     , (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]-2-
     propenamide   709652-80-2P,
     (E)-N-Methyl-N-[(3-methyl-1H-inden-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-
     tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     monohydrochloride
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (bactericide; compns. comprising multiple antibiotic agents and prepn
        of heterocycle FabI inhibitor)
IT   709651-73-0, (E)-3-[4-(4-Methoxybenzyl)-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl]-N-methyl-N-[(1-methyl-1H-indol-2-
     yl)methyl]-2-propenamide
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (compns. comprising multiple antibiotic agents and preparation of
        heterocycle FabI inhibitor)
IT   709650-77-1P, (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-
     1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]-2-
     propenamide   709650-81-7P,
     (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-
     7-yl)-N-methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide
     709651-72-9P, (E)-N-Methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-
     oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
     709652-37-9P, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-
     yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
     yl]ethanoic acid ethyl ester   709652-43-7P,
     (E)-[6-[2-[Methyl[(3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-
     oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid
     709652-44-8P, (E)-3-[3-(2,2-Dimethoxyethyl)-2-oxo-1,2,3,4-
     tetrahydropyrido[2,3-d]pyrimidin-6-yl]-N-methyl-N-[(3-
     methylbenzo[b]thiophen-2-yl)methyl]-2-propenamide   709652-45-9P
     , (E)-N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]-3-[2-oxo-3-(2-
     oxoethyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]-2-propenamide
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; compns. comprising multiple antibiotic agents and preparation
        of heterocycle FabI inhibitor)
IT   709652-36-8P, (E)-[6-[2-[Methyl[(1-methyl-1H-indol-2-
     yl)methyl]carbamoyl]vinyl]-2-oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-
     yl]ethanoic acid
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (bactericide; compns. comprising multiple antibiotic agents and preparation
        of heterocycle FabI inhibitor)
RN   709652-36-8  ZCAPLUS
```

```
L20  ANSWER 3 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
CN   Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid,
     1,4-dihydro-6-[(1E)-3-[methyl[(1-methyl-1H-indol-2-yl)methyl]amino]-3-oxo-
     1-propen-1-yl]-2-oxo-  (CA INDEX NAME)

Double bond geometry as shown.
```

```
OSC.G   3      THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT  5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L20  ANSWER 4 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2004:515512  ZCAPLUS
DN   141:71572
TI   Preparation of heterocyclic compounds as antibacterial agents
IN   Berman, Judd; Sampson, Peter; Pauls, Heinz W.; Ramnauth, Jailall, Manning,
     David Douglas; Surman, Matthew David; Xie, Dejian, Decornez, Helene Yvonne
PA   Affinium Pharmaceuticals, Inc., Can.
SO   PCT Int. Appl., 223 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
PI   WO--2004052890       A1    20040624   2003WO-US0038706       20031205
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA-----2508792       A1    20040624   2003CA-002508792       20031205
     AU--2003298937       A1    20040630   2003AU-000298937       20031205
     EP-----1575951       A1    20050921   2003EP-000796699       20031205
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP--2006513262       T     20060420   2005JP-000508475       20031205
     US-20060183908       A1    20060817   2003US-000537747       20031205
PRAI 2002US-00431406P     P     20021206
     2003US-00465583P     P     20030425
     2003WO-US0038706     W     20031205
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 141:71572
AB   Compds. of formula (Y1)a-A-CH(R1)-NR1CO-L-R2 [I; L = a bond, is alkyl,
     alkenyl, or cycloalkyl which may be substituted with one or more R1, A = a
     bicyclic heteroaryl ring of 8-12 atoms or a tricyclic ring oft 12-16
     atoms, wherein the heteroaryl rings contain 1-4 heteroatoms selected from
     N, S, and O, and wherein the heteroaryl rings are optionally substituted
     with one or more groups selected from C1-4 alkyl, CH2OH, OR, SR, CN,
     N(R)2, CH2N(R)2, NO2, CF3, CO2R, CON(R)2, COR, NRC(O)R, F, Cl, Br, iodo,
     and S(O)rCF3 (R = H, alkyl, alkaryl; r = 0-2); R1 = H, alkyl, cycloalkyl,
     aryl, or alkaryl; R2 = heterocyclyl] or pharmaceutically acceptable salts
     thereof are prepared. These compds. inhibit an NADH (or NADPH)-dependent
     enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated
     EnvM) which is believed to be a major biosynthetic enzyme and is a key
     regulatory point in the overall synthetic pathway of bacterial fatty acid
     biosynthesis and catalyzes the final step of fatty acid biosynthesis in
     some bacteria.  The present invention also relates to inhibitors and
     compns. comprising inhibitors of enzymes similar to FabI either
     structurally or functionally, such as, for example, FabK which is also
     believed to play a role in bacterial fatty acid synthesis.  In another
     aspect of the present invention, the antibacterial compds. of the present
     invention may be used to disinfect an inanimate surface by administering
     the antibacterial compound to the inanimate surface.  Thus,
     (E)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-
     yl)acrylic acid hydrochloride was condensed with
     N-methyl-N-(1-propylnaphthalen-2-ylmethyl)amine in DMF using
     diisopropylethylamine, 1-hydroxybenzotriazole hydrate, and
     1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride at room temperature
     for 18 h to give, after silica gel chromatog., 41%
     (E)-N-Methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-
     e][1,4]diazepin-7-yl)-N-[(1-propylnaphthalen-2-yl)methyl]acrylamide as a
     glassy orange solid and as a mixture of amide rotamers.  The compds. I
     inhibit FabI with a Ki of about 5 pM or less.
IT   709652-36-8P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (intermediate; preparation of heterocyclic compds. as enoyl-acyl carrier
        protein reductase FabI inhibitors and antibacterial agents)
IT   709652-37-9P    709652-40-4P    709652-43-7P
```

L14 ANSWER 4 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

769452-44-9P 769452-45-0P
RL: RCT (Reactant); SPN (Synthetic preparation); UNSP (Preparation); RACT (Reactant or reagent)
(intermediate; preps. of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

IT 769450-15-9P 769455-77-1P 769455-79-3P
769455-81-7P 769455-84-0P 769455-86-2P
769455-87-3P 769455-91-9P 769455-92-0P
769455-93-1P 769455-94-2P 769455-95-3P
769455-96-4P 769461-67-9P 769461-86-2P
769461-11-8P 769461-12-9P 769461-13-0P
769461-14-1P 769461-17-4P 769461-18-5P
769461-19-6P 769461-20-7P 769461-21-8P
769461-24-2P 769461-27-5P 769461-28-6P
769461-29-7P 769461-31-1P 769461-32-2P
769461-33-3P 769461-34-4P 769461-35-5P
769461-36-6P 769461-38-8P 769461-39-9P
769461-40-2P 769461-41-3P 769461-42-4P
769461-43-5P 769461-44-6P 769461-45-7P
769461-46-8P 769461-47-9P 769461-48-0P
769461-51-5P 769461-52-6P 769461-53-7P
769461-54-8P 769461-55-9P 769461-56-0P
769461-57-1P 769461-58-2P 769461-59-3P
769461-60-6P 769461-61-7P 769461-62-8P
769461-63-9P 769461-64-0P 769461-65-1P
769461-66-2P 769461-67-3P 769461-68-4P
769461-69-5P 769461-70-8P 769461-71-9P
769461-72-0P 769461-73-1P 769461-74-2P
769461-75-3P 769461-76-4P 769461-77-5P
769461-78-6P 769461-79-7P 769461-80-0P
769461-81-0P 769461-82-1P 769461-83-2P
769461-84-3P 769461-85-4P 769461-86-5P
769461-87-6P 769461-88-7P 769461-89-8P
769461-90-1P 769461-91-2P 769461-92-3P
769461-93-4P 769461-94-5P 769461-95-6P
769461-96-7P 769461-97-8P 769461-98-9P
769462-00-5P 769462-01-6P 769462-02-7P
769462-03-8P 769462-04-9P 769462-05-0P
769462-06-1P 769462-07-2P 769462-08-3P
769462-09-4P 769462-10-7P 769462-11-8P
769462-12-9P 769462-13-0P 769462-14-1P
769462-15-2P 769462-16-3P 769462-17-4P
769462-18-5P 769462-19-6P 769462-20-9P
769462-21-0P 769462-22-1P 769462-23-2P
769462-24-3P 769462-25-4P 769462-26-5P
769462-27-6P 769462-28-7P 769462-29-8P
769462-30-1P 769462-31-2P 769462-32-3P
769462-33-4P 769462-34-5P 769462-35-6P
769462-36-7P 769462-37-8P 769462-38-9P
769462-39-0P 769462-40-3P 769462-41-4P
769462-42-5P 769462-43-6P 769462-44-7P
769462-45-8P 769462-46-9P 769462-47-0P
769462-48-1P 769462-49-2P 769462-50-5P
769462-51-6P 769462-52-7P 769462-53-8P
769462-54-9P 769462-55-0P 769462-56-1P
769462-57-2P 769462-58-3P 769462-59-4P
769462-60-7P 769462-61-8P 769462-62-9P
769462-63-0P 769462-64-1P 769462-65-2P
769462-66-3P 769462-67-4P 769462-68-5P
769462-69-6P 769462-70-9P 769462-71-0P
769462-72-1P 769462-73-2P 769462-74-3P
769462-75-4P 769462-76-5P 769462-77-6P
769462-78-7P 769462-79-8P 769462-80-2P
769462-81-3P 769462-82-4P 769462-83-5P
769462-84-6P 769462-85-7P 769462-86-8P
769462-87-9P
RL: PAC (Pharmacological activity); RPH (Synthetic preparation); TEM (Technical or engineered material use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

IT 769681-73-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

IT 769682-26-8P
RL: PAC (Pharmacological activity); RCT (Reactant); RPH (Synthetic preparation); TEM (Technical or engineered material use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of heterocyclic compds. as enoyl-acyl carrier protein reductase FabI inhibitors and antibacterial agents)

RN 769682-26-8P ICAPLUS
CN Pyrimidine, 5-[(2-methoxyethyl)[(1-methyl-1H-indol-3-yl)methyl]amino]-3-oxo-2-propene-4-yl]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.

L26 ANSWER 4 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs hitstr 131 tot
```



II

AB The invention is directed to antibacterial compds. comprising an NADH (or NADPH) dependent enoyl-ACP reductase (FabI) inhibitor, such as previously designated AcetU inhibitor of formula (R1a-A-CH(R1)-NR1CO)n-R2 (I) and at least one other antibiotic/antibacterial agent (s = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted aromatic heterocaryl of 8-11 atoms or a tricyclic ring of which at least one ring is aromatic; R1 = H, halo, alkyl, alkenyl, OH, NH2, cycloalkyl, alkaryl; R2 = heteroaryl; a = 0-4; T1 = -(CH2)1-CH(NHAR3)-R4 + water solubilizing group; R3 = H, cyclo/alkyl; z = 0-4). The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, formulation of 5-nitrofuran-2-yl-(1-methyl-1H-pyrrol-2-yl)-2-oxo-ethyl-pyrrolidine-2-carboxylic acid (preparation given), coupling of this product with 5-methyl-N-(3-methylaminofuran-2-yl)methylpyrimidine, and acidulation of the free base (no data) with TFA gave pyridinylsepine II•TFA. Selected I inhibited FabI with a K i of 1 nM, an MIC (ultimal inhibitory concentration) against M. tuberculosis of 10 nM.

IT **620175-24-4** **620175-32-0** **620175-34-2**
620178-36-6 **620178-40-0** **620179-43-3**



RN 620175-40-0 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1-benzofuranyl)methyl]-2-(2,6,7,8-tetrahydro-7-oxo-1,8-naptyridin-2-yl)-, (9E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-43-3 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2,6,7,8-tetrahydro-7-oxo-1,8-naptyridin-2-yl)-, (9E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 620175-44-4 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(2,6,7,8-tetrahydro-7-oxo-1,8-naptyridin-2-yl)-, (9E)- (CA INDEX NAME)

Double bond geometry as shown.

620175-44-4 1056138-54-7
RL: BPRN (Properties)
(Compos. comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and prepn. of the heterocycle FabI inhibitor)
RN 620175-44-4 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-2-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-32-0 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-2-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-34-2 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-2-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620178-38-8 SCAPLUS
CN 2-Propenamide, N-[3-benzofuranylmethyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-



IT **894801-52-8P** (E)-N-(3-Isopropyl-1-propynebenzyl)-N-methyl-3-(2-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-2-yl)-2-propenamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bacteriocides; compos. comprising multiple antibiotic agents and preparation including FabI inhibitor)

RN 894801-52-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(3-methylbenzyl)-2-propynepenzyl]methyl]-3-(2,2,4,4-tetramethyl-2-oxo-1H-pyrrolo[2,3-c]pyridin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

IT **894897-72-1P** (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]-2-propenamide **894897-73-2P** (E)-N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-N-[(1-methyl-1,2,3,4-tetrahydroquinolin-3-yl)methyl]-2-propenamide **620174-21-9P** (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-methyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-23-0P** (E)-N-[(1H-Indol-3-ylmethyl)]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-24-1P** (E)-N-[(1-Acetyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-25-2P** (E)-N-[(3-[(Acetylamino)methyl]-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-26-3P** (E)-N-Methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-27-4P** (E)-N-[(3-Chloro-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-28-5P** (E)-N-[(3-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-29-6P** (E)-N-[(4-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-30-9P** (E)-N-[(5-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-31-0P** (E)-N-[(6-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-32-1P** (E)-N-[(7-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-33-2P** (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-34-3P** (E)-N-[(5-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-35-4P** (E)-N-[(6-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-36-5P** (E)-N-[(7-Chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-37-6P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-38-7P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-39-8P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-40-9P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-41-0P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-42-1P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-43-2P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-44-3P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-45-4P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-46-5P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-47-6P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-48-7P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-49-8P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-50-1P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-51-2P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-52-3P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-53-4P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-54-5P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-55-6P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-56-7P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-57-8P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-58-9P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-59-0P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-60-3P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-61-4P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-62-5P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-63-6P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-64-7P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-65-8P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-66-9P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-67-0P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-68-1P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-69-2P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-70-5P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-71-6P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-72-7P** (E)-N-[(1-Benzyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide **620174-73-8P** (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **620174-74-9P** (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide **620174-75-0P** (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide **620174-76-1P** (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide **620174-77-2P** (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-

L3) ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
cono-6,7,8-tetrahydro-5H-pyrido[3,2-b][1,4]oxazin-3-yl]-2-propenamide
626174-73-0DP, (E)-N-[(3-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626174-80-9, (E)-N-[(3-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626174-81-0, (E)-N-[(3-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626174-82-1, (E)-N-(diaphenylmethyl)-3-(7-cono-5,6,7,8-tetrahydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626174-84-3P, (E)-N-(benzofuran-3-ylmethyl)-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626174-85-4P, (E)-N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-00-0P, (E)-N-[(1,3-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-01-1P, (E)-N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-02-2P, (E)-N-[(1-ethyl-3-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-03-3P, (E)-N-[(1-ethyl-5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-04-4P, (E)-N-[(4-methoxy-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-05-5P, (E)-N-[(5-methoxy-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-06-6P, (E)-N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-07-7P, (E)-N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-08-8P, (E)-N-[(1,3-dimethyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-09-9P, (E)-N-[(1-ethyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-10-2P, (E)-N-[(1-ethyl-3-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-11-3P, (E)-N-[(1-ethyl-5-fluoro-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-12-4P, (E)-N-[(1-ethyl-5-methoxy-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-13-5P, (E)-N-[(1-ethyl-6-methoxy-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-14-6P, (E)-N-[(1-ethyl-7-methoxy-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-15-7P, (E)-N-[(2,3-dihydro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-16-8P, (E)-N-[(2,3-dihydro-1-methyl-1H-indol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-17-9P, (E)-N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-18-0P, (E)-N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-19-1P, (E)-N-[(1,3-dimethyl-1H-indol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-20-4P, (E)-N-[(1-ethyl-1H-indol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-21-5P, (E)-N-[(1-ethyl-3-methyl-1H-indol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-22-6P, (E)-N-[(1-ethyl-6-methoxy-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-23-7P, (E)-N-[(1-ethyl-7-methoxy-1H-indol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-24-8P, (E)-N-[(6-methoxy-1-methyl-1H-indol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-25-9P, (E)-N-[(5-methoxy-1-methyl-1H-indol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-26-0P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-27-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-28-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-29-3P, (E)-N-[(1,3-dimethyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-30-6P, (E)-N-[(1-ethyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-31-7P, (E)-N-[(1-ethyl-3-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-32-8P, (E)-N-[(1-ethyl-6-methoxy-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-33-9P, (E)-N-[(1-ethyl-7-methoxy-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-34-0P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-35-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-36-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-37-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-38-4P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-39-5P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-40-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-41-9P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-42-0P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-43-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-44-2P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-45-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-46-4P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-47-5P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-48-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-49-7P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-50-0P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-51-1P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-52-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-53-3P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-54-4P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-55-5P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-56-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-57-7P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-58-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-59-9P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-60-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-61-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-62-4P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-63-5P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-64-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-65-7P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-66-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-67-9P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-68-0P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-69-1P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-70-4P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-71-5P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-72-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-73-7P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-74-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-75-9P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-76-0P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-77-1P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-78-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-79-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-80-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-81-7P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-82-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-83-9P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-84-0P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-85-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-86-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-87-3P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-88-4P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-89-5P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-90-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-91-9P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-92-0P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-93-1P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-94-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-95-3P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-96-4P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-97-5P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-98-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626175-99-7P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-00-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-01-4P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-02-5P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-03-6P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-04-7P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-05-8P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-06-9P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-07-0P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-08-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-09-2P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-10-5P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-11-6P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-12-7P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-13-8P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-14-9P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-15-0P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-16-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-17-2P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-18-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-19-4P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-20-7P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-21-8P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-22-9P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-23-0P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-24-1P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-25-2P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-26-3P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-5-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-27-4P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-6-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-28-5P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-7-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-29-6P, (E)-N-[(6-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide
626176-30-9P, (E)-N-[(5-methoxy-1-methyl-1H-indazol-3-yl)methyl]-N-methyl-3-(7-cono-6,8-dihydro-5-oxo-5,6-naphthyridin-3-yl)-2-propenamide

L3) ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 626176-10-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-8-methyl-2-oxopyrido[3,2-b]pyrazin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626176-12-7 ZCAPLUS
CN 2-Propenamide, N-(1H-indol-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626176-13-8 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626176-14-9 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626176-15-0 ZCAPLUS
CN 2-Propenamide, N-[(3-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626176-16-1 ZCAPLUS
CN 2-Propenamide, N-[(3-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 623176-12-8 SCAPLUS
CN 2-Propenamide, N-[5-fluoro-1-methyl-1H-indol-3-ylmethyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-14-9 SCAPLUS
CN 2-Propenamide, N-[(6-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-19-0 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 623176-88-9 SCAPLUS
CN 3-Ketonamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623177-73-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-2H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623174-75-6 SCAPLUS
CN 2-Propenamide, N-[[3-(hydroxymethyl)-1H-indol-5-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623174-77-8 SCAPLUS

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 618174-63-2 SCAPLUS
CN 2-Propenamide, N-[(7-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 618174-65-4 SCAPLUS
CN 3-Propenamide, N-[(7-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 618174-67-6 SCAPLUS
CN 2-Propenamide, N,3-dimethyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 618174-78-9 SCAPLUS
CN 3-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 618174-85-2 SCAPLUS
CN 2-Propenamide, N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 618174-91-8 SCAPLUS
CN 3-Propenamide, N-methyl-N-(3-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628174-94-9 SCAPLUS
CN 2-Propenamide, N-(2-nitrophenyl)methyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-98-3 SCAPLUS
CN 2-Propenamide, N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-99-4 SCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628176-04-4 SCAPLUS
CN 2-Propenamide, N-[(7-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-14-6 SCAPLUS
CN 2-Propenamide, N-[(7-hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-24-8 SCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 628175-10-5 SCAPLUS
CN 2-Propenamide, N-[(1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628174-81-1 SCAPLUS
CN 2-Propenamide, N-[(1,6-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628175-62-2 SCAPLUS
CN 2-Propenamide, N-[(1,4-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628175-63-3 SCAPLUS
CN 2-Propenamide, N,1-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 628176-05-7 SCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628175-64-4 SCAPLUS
CN 2-Propenamide, N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628176-15-7 SCAPLUS
CN 2-Propenamide, N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628176-25-9 SCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-12-6 SCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indon-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 621175-26-1 SCAPLUS
CN 2-Propenamide, N-[(4-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 621175-22-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-(3-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 621175-24-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-(1-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 744378-28-0 SCAPLUS
CN 2-Propenamide, N-[(2,8-dihydro-3H-pyrrolo[3,2-a]indol-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 744379-24-3 SCAPLUS
CN 2-Propenamide, 3-(6-amino-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 744379-21-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-(3-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 621175-78-2 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-(2-methoxyethyl)-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 621176-18-2 SCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,3,4-tetrahydro-6-[(E)-3-[methyl[(1-methyl-1H-indol-3-yl)methyl]amino]-3-oxo-1-propen-1-yl]-5-oxo-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 621176-39-5 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 744378-50-5 SCAPLUS
CN 2-Propenamide, N-[(1,2-dihydro-5-acenaphthylen-1-yl)methyl]-3-(1,2,3,4-tetrahydro-3-[3-(4-morpholinyl)ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 744378-84-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylisoxazolo[4]thiolo-1-ylmethyl)-3-(1,2,3,4-tetrahydro-3-[3-(4-morpholinyl)propyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 744378-40-5 SCAPLUS
CN Pyrido[2,3-d]pyrimidine-3(2H)-propanoic acid, 1,4-dihydro-4-[(2E)-3-[methyl[(3-methylisoxazolo[4]thiolo-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.

RN 744379-41-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-ylmethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 942278-42-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 942278-43-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylthieno[3',2':4,5]thieno[2,3-d]pyrimidin-4-yl)methyl]-3-(5,6,7,8-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-d][1,4,6]triazepin-7-yl)- (CA INDEX NAME)



RN 942278-44-9 SCAPLUS
CN 2-Propenamide, N-[(2-chloro-4-acetamidophenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e][1,4,6]diazepin-7-yl)- (CA INDEX NAME)

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(2,3,4,5-tetrahydro-3,5-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4,6]diazepin-7-yl)- , hydrochloride (3:1), (3E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-24-2 SCAPLUS
CN 2-Propenamide, N-[(4-chloro-2-ethoxyphenyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-25-7 SCAPLUS
CN 2-Propenamide, N-[(5-chloro-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,5-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4,6]diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-36-6 SCAPLUS
CN 2-Propenamide, N-[(3-methoxy-5-(2-methylpropoxy)pheny1]methyl]-N-methyl-3-(5,6, 7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 942278-45-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(5-methylfuro[3',2':4,5]thieno[2,3-d]pyrimidin-4-yl)methyl]-3-(5,6,7,8-tetrahydro-3-[(3-(4-morpholinyl)ethyl)-2-oxopyrido[2,3-d]pyrimidin-4-yl)- (CA INDEX NAME)



RN 942378-46-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 894851-34-9 SCAPLUS
CN 2-Propenamide, N-[(5-ethoxy-3-(trifluoromethoxy)phenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)- , hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-19-5 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-propoxy-5-(trifluoromethoxy)phenyl)methyl]-3-

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894851-41-8 SCAPLUS
CN 2-Propenamide, N-[(2-ethoxy-2-(3-methylethylphenyl)ethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894851-47-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[[3-(3-methylbutoxy)-5-(2-propynyloxy)phenyl]methyl]-3-(2,3,4,5-tetrahydro-3,5-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4,6]diazepin-7-yl)- (CA INDEX NAME)



● HCl

RN 894851-48-2 SCAPLUS
CN 2-Propenamide, N-methyl-N-[[5-(3-methylethyl)-2-propynylphenyl]methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown

L31 ANSWER 1 OF 11 ICM/PLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894851-56-0 ICM/PLUS
CN D-Progenamide, N-[[3-methoxy-2-[2-methylpropoxy]phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-7,3-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1/1). (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-70-9 ICM/PLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-7-[(2S)-2-[[[3-[3-methylbenzo[b]thien-2-yl]methyl]amino]-3-oxo-1-propyl]-4-[(2-oxo-, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 894851-86-0 ICM/PLUS
CN D-Progenamide, N-[[3-ethyl-2-benzofuranyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ICM/PLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894851-93-7 ICM/PLUS
CN D-Progenamide, N-ethyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2,3,4,5-tetrahydro-2,9-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-97-3 ICM/PLUS
CN D-Progenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-08-6 ICM/PLUS
CN D-Progenamide, N-[[3-ethoxy-2-(3-methylbutyl)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ICM/PLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894851-84-6 ICM/PLUS
CN 1-Propanamine, N-methyl-N-[(2-propyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-2,3-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-90-3 ICM/PLUS
CN D-Progenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894851-95-8 ICM/PLUS
CN D-Progenamide, N-[(3-methoxy-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,9-dimethyl-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ICM/PLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894852-11-0 ICM/PLUS
CN D-Progenamide, N-[(3-methoxy-2-(2-methylpropoxy)phenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-23-6 ICM/PLUS
CN D-Progenamide, N-[[3-cyano-1H-indol-2-yl]methyl]-N-methyl-3-(6,6,7,8-tetrahydro-1-oxo-1,9-oxipicolido-9-yl)-, (CA INDEX NAME)

RN 894853-37-0 ICM/PLUS
CN D-Progenamide, N-[(3-ethoxy-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e][1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 894852-39-2 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(2,3,4,5-tetrahydro-4-methyl-2-oxo-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-45-0 SCAPLUS
CN 2-Propenamide, N-[(9-chloro-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-46-1 SCAPLUS
CN 2-Propenamide, N-[(E)-indol-5-ylmethyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-47-2 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-5-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-48-3 SCAPLUS
CN 2-Propenamide, N-[(3-(1,1-dimethylethyl)-2-propoxyphenyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-51-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-4-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-52-9 SCAPLUS

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-54-1 SCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-3,3-dimethyl-5-benzofuranyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-58-5 SCAPLUS
CN 2-Propenamide, N-(1H-indol-4-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-66-5 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-5-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-77-8 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-2-methylbenzo[b]thien-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-78-9 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-79-0 SCAPLUS
CN 2-Propenamide, N-[(5-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-80-3 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-(1-methylethyl)-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-81-4 ZCAPLUS
CN 7-Propenamide, N-(5-hydroxypentyl)-N-methyl-2-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-82-5 ZCAPLUS
CN 2-Propenamide, N-(benzo[b]thien-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894892-84-7 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-4-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 894852-86-9 ZCAPLUS
CN 2-Propenamide, N-(1,3-dimethyl-1H-indol-2-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894853-37-1 ZCAPLUS
CN 2-Propenamide, N-[(2,3-dimethyl-1H-indol-2-yl)methyl]-N-methyl-2-(2,2,6,8-tetramethyl-4-oxo-4-pyranyl)-3-pyridyl]-3,5-di-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-91-9 ZCAPLUS
CN 2-Propenamide, N-(1-ethyl-3-methyl-1H-indol-2-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894853-46-8 ZCAPLUS
CN 2-Propenamide, N-[(4,6-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 894852-85-8 ZCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-4-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-89-2 ZCAPLUS
CN 2-Propenamide, N-[1H-benzimidazol-6-ylmethyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 894852-90-5 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(5-methyl-2-benzofuranyl)methyl]-3-(2,3,6,7-tetrahydro-2-oxo-4-pyranyl-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 894852-98-3 ZCAPLUS
CN 2-Propenamide, N-[(3,7-dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.



RN 894853-45-3 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-4,6-dimethyl-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 918983-44-9 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[[2-[1-methylethyl]-2-propoxyphenyl]methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT 338629-81-1P
RL: BPH (Biochemical process); PREP (Preparation)
(preparation of naphthyridinone antisitic agents and preparation of intermediate fast inhibitor)
RN 338629-81-1 ZCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT 748278-27-8P 748278-53-0P 894851-19-8P
894851-23-1P 894851-35-9P
(E)-N-(3-Chloro-2-propoxyphenyl)-3-(3,8-dimethyl-2-oxo-2,3,6,7-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-2-propenamide

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

894851-51-9P **894851-57-1P** **894851-70-0P**
894851-92-2P, (E)-(5,6-Dihydrobenzofuro-2,3-d)methyl(1-N-methyl-3-(2-oxo-3,4,5-tetrahydro-1H-pyrido[3,4-b][1,4]diazepin-7-yl)-2-propenamide
894851-95-5P, (R)-3-(3,5-Dimethyl-4-oxo-2,4,5,6-tetrahydro-1H-pyrrolo[3,4-c][1,6]naphthyridin-9-yl)-N-[(3-propylbenzofuran-2-yl)methyl]-2-propenamide **894852-92-4P**, (E)-N-(5,6-Dihydrobenzofuro-2,3-d)methyl-N-methyl-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide **894851-94-4P**, (R)-3-(3,5-Dimethyl-4-oxo-2,4,5,6-tetrahydro-1H-pyrrolo[3,4-c][1,6]naphthyridin-9-yl)-N-[(4-methoxy-2-propylphenyl)methyl]-2-propenamide **894852-05-0P**, (E)-N-(2-Ethynyl-3-propylbenzyl)-3-(4-(4-methoxybenzyl)-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-2-propenamide **894852-09-4P**, (E)-N-[(2-Ethynyl-3-propylphenyl)methyl]-3-(4-(4-methoxybenzyl)-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-2-propenamide
RL: BAC (Biological activity or effector, except adverse); BSP (Biological study, properties); FMU (Formation, unclassified); PAC (Pharmacological activity); PRP (Properties); RACT (Reactant or reagent)
(preparation of diazepine derivs. comprising multiple antithiotic agents and propargyl substituents for use as serotonin 5-HT6 receptor inhibitors)

RN 764378-71-4 SCAPLUS
CN 2-Propenamide, N-(4-((diphenylmethyl)amino)-5,6,7,8-tetrahydro-7-oxo-1,6-naphthyridin-3-yl)-N-methyl-3-(1-methyl-1H-indol-3-yl)methyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 764379-53-6 SCAPLUS
CN Pyrido[2,3-b]pyrimidine-3(2H)-acetic acid, 1,4-dihydro-4-[[(E)-3-[methyl[(3-methylisoxazol-5-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, ethyl ester, sodium salt (1:1) (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-18-6 SCAPLUS
CN 2-Propenamide, N-[[2-ethoxy-3-(trifluoromethoxy)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-4-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L32 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 894851-97-1 SCAPLUS
CN 2-Propenamide, N-[[3-methoxy-5-(1-methylcyclopropyl)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-4-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-52-0 SCAPLUS
CN 1,4-Oxazepino[2,3-c]quinoline-2-carboxylic acid, 1,2-dihydro-4-[(E)-3-methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-oxo-1-propen-1-yl]-3-oxo-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-93-2 SCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[3,2-e]-1,4-diazepin-7-yl)-, (E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-99-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-propyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[3,2-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 894851-23-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-propyn-3-(trifluoromethoxy)phenyl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-4-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-35-5 SCAPLUS
CN 2-Propenamide, N-[(3-chloro-2-propoxyphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-51-9 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-(1-methylethyl)-3-propoxyphenyl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)- , (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 894851-93-6 SCAPLUS
CN 2-Propenamide, N-[(3-ethyl-2-benzofuranyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-94-4 SCAPLUS
CN 2-Propenamide, N-[(3-methoxy-2-propylphenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-96-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2,3,4,5-tetrahydro-3,3-dimethyl-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 894851-99-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(2,3,4,5-tetrahydro-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (2E)- (CA INDEX NAME)

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.

RN 496652-68-6 SCAPLUS
CN 3-Propionamide, N-[(2-ethoxy-3-(1-methylethyl)phenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-[(4-methoxyphenyl)methyl]-2-oxo-1H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (3S)- (CA INDEX NAME)

Double bond geometry as shown.

RN 496652-10-1 SCAPLUS
CN 3-Propionamide, N-[3-methoxy-2-(2-methylpropoxy)phenyl]methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-oso-3H-pyrido[2,3-e]-1,4-diazepin-7-yl)-, (3S)- (CA INDEX NAME)

Double bond geometry as shown.

GAC H 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L31 ANSWER 2 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

GAC H 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:283474 SCAPLUS
DN 142:336396
TI Preparation of tetrahydropyranoxalines as M2 acetylcholine receptor agonists for the treatment of cardiovascular diseases
IN Gohl, Alexander; Roland, Peter; Telan, Leila; Peters, Jan-Georg; Lustig, Klemens; Kast, Raimund; Maarten, Klaas; Mikusa, Johannes-Peter; Trarl, Hans
PA Bayer Healthcare Ag, Germany
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2005028457	A1	20050331	2004WO-EP009936	20040907 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	DE---102439298	A1	20050414	2003DE-10343298	20030918 <--
PRAI	2003DE-10343298	A	20030918	<--	
OS	MARPAT 142:336396				
GI					

* STRUCTURES DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OUTLINE PRINT *

AB Title compds. I [Y = A-N1; A = (un)substituted alkandiyl (oic); X = CH, N; R1 = (un)substituted Ph, pyridyl (oic); R2 = (un)substituted cycloalkyl; R3 = alkyl, cycloalkyl; R4 = H, alkyl; R5 = H, alkyl] and their pharmaceutically acceptable salts were prepared. For example, AAC mediated coupling of carboxylic acid II e.g., prepared from 4-chloro-3-nitrobenzoic acid, with 4-methoxybenzylamine, followed by reduction afforded tetrahydroquinoxaline III in 13% yield. In human M2 acetylcholine receptor assay, 6-examples of compds. I exhibited EC50 values ranging from 1-570 nM, e.g., the EC50 value of tetrahydroquinoxaline III was 678 nM. Compds. I are claimed to be useful for the treatment of cardiovascular diseases.

IT **849572-36-0P**, 4-Cyclopropyl-N-[(S)-1-[4-methoxybenzyl]ethyl]-3-oxo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydropyranoxalines as M2 acetylcholine receptor agonists for the treatment of cardiovascular diseases)

RN 849572-36-0 SCAPLUS
CN Pyrido[2,3-b]pyrazine-7-carboxamide, 4-cyclopropyl-1,2,3,4-tetrahydro-N-[(1S)-1-(4-methoxyphenyl)ethyl]-3-oxo- (CA INDEX NAME)

Absolute stereochemistry.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:199427 SCAPLUS
DN 141:216351
TI Pharmaceuticals comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocyclic FabI inhibitors
IN Berman, Judd M.; Schmid, Molly B.; Hendlein, John D.; Hapian, Herman
PA Affinium Pharmaceuticals, Inc., Can
SO PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004081194	A2	20040920	2004WO-CA000124	20040217 <--
	WO--2004081194	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	CA----2516837	A1	20040920	2004CA-2516837	20040217 <--
	EP----1603877	A2	20051228	2004EP-0707125?	20040217 <--
	EP----1603877	B1	20080101		
	R: AL, AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	JP--2006523591	T	20061012	2004JP-0506426	20040217 <--
	AT----401945	T	20080815	2004AT-0707125?	20040217 <--
	US-20060014695	A1	20060119	2005US-0602312?	20050713 <--
PRAI	2003US-0448339P	P	20030217	<--	
	2003US-0474870P	P	20030604	<--	
	2003US-0540377P	P	20030716	<--	
	2004WO-IB000236	W	20040217	<--	

ASSIGNMENT HISTORY AVAILABLE IN LSS DISPLAY FORMAT
OS MARPAT 141:216351
GI

AB The invention is directed to antibacterial compns. comprising an ANDH (or NADH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI) inhibitor previously designated EnoM; inhibitor of formula (I)[A-N-CH(R3)-NR3CH2-L-R2 (S) and at least one other antibiotic/antibacterial agent [A = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1, A = (un)substituted aryl, heteroaryl, or heterocyclyl; L = a linking group of 1[-4 atoms, containing 1-4 heteroatoms selected from N, O, and S; R2 = cycloalkyl, alk/enyl; R2 = heterocyclyl, = # 0-4; T1 = -(CH2)n-CO-NHOR5; R5 = water solubilizing group; R5 = H, cycloalkyl, = 0-4]. The antibacterial composition exhibits a synergistic antibacterial effect compared to the individual components. Thus, reacting 7-bromo-5,5-dimethyl-1,5,6,7-tetrahydropyrido[2,3-d][1,4]oxazepin-2-one (preparation given) with 4-methoxybenzylamine, 4-(dimethylamino)benzaldehyde, and (1-methylcyclohexyl)methylamine (preparation given), followed by oxidation gave dicarbonyl salt II.MeOH. Selected I inhibited FabI with = #1, < 1 nM. Selected dicarbonyl salts showed concentrations = 0.015 μg/mL and an MIC90 = 10 nM.

IT **429175-83-1** **429176-66-2** **429176-68-4** **429176-68-2** **1072464-02-6** **1072464-03-7** **1072464-04-0**
RL: PROPH (Prophetic)

L3) ANSWER 3 OF 11 ICAPLUS COPYRIGHT 2009 ACS on STN (Continued)

(Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitor)

RN 623175-34-5 ICAPLUS
CN 2-Propenamide, N-[3-methoxy-2-benzofuranyl)methyl]-3-(6,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 623175-38-9 ICAPLUS
CN 2-Propenamide, N-ethyl-N-[(3-oxo-2-benzofuranyl)methyl]-3-(6,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 623175-40-0 ICAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-3-benzofuranyl)methyl]-3-(6,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 623175-43-3 ICAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-2-yl)ethyl]-3-(6,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L3) ANSWER 3 OF 11 ICAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT **484267-21-8**, (E)-N-Methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-N-[(1-phenylcyclopropyl)methyl]-2-propenamide
623174-29-8, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-31-0, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-33-2, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-35-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-40-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623174-41-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-42-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
623174-43-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,7-naphthyridin-3-yl)-2-propenamide
623174-44-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,5-naphthyridin-3-yl)-2-propenamide
623174-45-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,2-naphthyridin-3-yl)-2-propenamide
623174-46-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,4-naphthyridin-3-yl)-2-propenamide
623174-47-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-5-yl)-2-propenamide
623174-48-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-49-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-50-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-51-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-52-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623174-53-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide
623174-54-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-55-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-56-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-57-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-58-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-59-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-60-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623174-61-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide
623174-62-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-63-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-64-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-65-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623175-01-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623175-02-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623175-03-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-04-0, (E)-N-[(1,6-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-05-1, (E)-N-[(1,7-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-06-2, (E)-N-[(1,5-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-07-3, (E)-N-[(1,4-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-08-4, (E)-N-[(1,2-Dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-09-5, (E)-N-[(1-Methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-10-8, (E)-N-[(1-Methoxy-2-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-11-9, (E)-N-[(1-Methoxy-3-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-12-0, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-13-1, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,7-naphthyridin-3-yl)-2-propenamide
623175-14-2, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,5-naphthyridin-3-yl)-2-propenamide
623175-15-3, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,2-naphthyridin-3-yl)-2-propenamide
623175-16-4, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,4-naphthyridin-3-yl)-2-propenamide
623175-17-5, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-5-yl)-2-propenamide
623175-18-6, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623175-19-7, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623175-20-0, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623175-21-1, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623175-22-2, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide
623175-23-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623175-24-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide
623175-25-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623175-26-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623175-27-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623175-28-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623175-29-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623175-30-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623175-31-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623175-32-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623175-33-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide

L3) ANSWER 3 OF 11 ICAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 428179-44-2 ICAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-3-yl)ethyl]-3-(6,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 1672664-02-6 ICAPLUS
CN 2-Propenamide, N-methyl-N-[1-(6-pyrrolo[3,2-b]pyridin-3-ylethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,6-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 1672664-03-7 ICAPLUS
CN 2-Propenamide, N-methyl-N-[1-(6-pyrrolo[3,2-c]pyridin-3-ylethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,6-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 1672664-04-8 ICAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1H-pyrrolo[2,3-c]pyridin-3-ylethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,6-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L3) ANSWER 3 OF 11 ICAPLUS COPYRIGHT 2009 ACS on STN (Continued)

methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-69-7, (E)-N-[(4-Mercaptop-1-methyl-1H-indol-3-yl)ethyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-68-6, (E)-N-[(4-Mercaptop-1H-indol-3-yl)ethyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-19-7, (E)-N-[(4-Mercaptop-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-18-6, (E)-N-[(4-Mercaptop-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-20-0, (E)-N-[(4-Fluoro-1-methyl-1H-indol-3-yl)ethyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-22-2, (E)-N-[(4-Fluoro-1H-indol-3-yl)ethyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-21-1, (E)-N-[(4-Fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
428178-23-3, (E)-N-[(4-Fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
1672664-05-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
1672664-06-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-5-yl)-2-propenamide
1672664-07-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-7-yl)-2-propenamide
1672664-08-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-8-yl)-2-propenamide
1672664-09-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-2-propenamide
1672664-10-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-4-yl)-2-propenamide
623174-29-8, (E)-N-Methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-31-0, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-33-2, (E)-N-Methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-35-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-40-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623174-41-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro[1,3-d]pyridazino[4,5-g][1,3]pyridazin-6-yl)-2-propenamide
623174-42-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-2-propenamide
623174-43-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,7-naphthyridin-3-yl)-2-propenamide
623174-44-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,5-naphthyridin-3-yl)-2-propenamide
623174-45-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,2-naphthyridin-3-yl)-2-propenamide
623174-46-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,4-naphthyridin-3-yl)-2-propenamide
623174-47-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,6-naphthyridin-5-yl)-2-propenamide
623174-48-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-49-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-50-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-51-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-52-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623174-53-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide
623174-54-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-55-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-56-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-57-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-58-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-59-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-60-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide
623174-61-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-5-yl)-2-propenamide
623174-62-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-63-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-64-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-65-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-66-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-67-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-68-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-69-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-70-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-71-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-72-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-73-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-74-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-75-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-76-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-77-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-78-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-79-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-80-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-81-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-82-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-83-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-84-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-85-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-86-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-87-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-88-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-89-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-90-1, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-91-2, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-92-3, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-93-4, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-94-5, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-95-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623174-96-7, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide
623174-97-8, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-propenamide
623174-98-9, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-6-yl)-2-propenamide
623174-99-0, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-7-yl)-2-propenamide
623175-00-6, (E)-N-[(1-Ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(7-oxo-6,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2-propenamide

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
NAME)

Double bond geometry as shown.



RN 628174-11-0 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(3,3,3,4-tetrahydro-3-methyl-2-oxopyrido[3,2-b]pyrazin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-12-1 SCAPLUS
CN 2-Propenamide, N-(1H-indol-3-ylmethyl)-N-methyl-3-(3,4,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-24-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-(phenylmethyl)-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628174-43-7 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-13-9 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-44-8 SCAPLUS
CN 2-Propenamide, N-[(6-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628174-29-9 SCAPLUS
CN 3-Propenamide, N-[[1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-33-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methylthieno[4]thien-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-40-5 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628174-45-0 SCAPLUS
CN 2-Propenamide, N-[(7-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628174-42-7 SCAPLUS
CN 2-Propenamide, N-[(7-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-46-1 SCAPLUS
CN 2-Propenamide, N-[(7-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628174-47-2 SCAPLUS
CN 2-Propenamide, N,2-dimethyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628176-89-3 SCAPLUS
CN 4-Morpholinamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628176-73-1 SCAPLUS
CN 2-Propenamide, N-ethyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-78-6 SCAPLUS
CN 2-Propenamide, N-[(2-cyclopentyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628176-91-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-(2-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628177-84-9 SCAPLUS
CN 2-Propenamide, N-(2-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-88-2 SCAPLUS
CN 2-Propenamide, N-[5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-99-6 SCAPLUS
CN 2-Propenamide, N-[(4-chloro-3-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628174-77-8 SCAPLUS
CN 2-Propenamide, N-ethyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(6,7,8,9-tetrahydro-8-oxo-5H-pyrido[2,3-b]azepin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-79-0 SCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628174-69-1 SCAPLUS
CN 4-Morpholinamide, N-[(5-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Double bond geometry as shown.



RN 628175-60-9 SCAPLUS
CN 2-Propenamide, N-[(1,5-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-51-1 SCAPLUS
CN 2-Propenamide, N-[(1,4-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-60-2 SCAPLUS
CN 2-Propenamide, N-[(1,6-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628175-82-3 SCAPLUS
CN 2-Propenamide, N-[(1,5-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-84-4 SCAPLUS
CN 2-Propenamide, N-[(7-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-86-6 SCAPLUS
CN 2-Propenamide, N-[(5-hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628175-10-2 SCAPLUS
CN 2-Propenamide, N-(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-12-4 SCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indazol-5-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-20-4 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(6,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628175-06-6 SCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-07-7 SCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-08-8 SCAPLUS
CN 2-Propenamide, N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 628175-09-9 SCAPLUS
CN 2-Propenamide, N-methyl-N-[3-quinolylmethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-24-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-naphthalenylmethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-26-0 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(1,2,3,4-tetrahydro-3-[2-methoxyethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628175-28-2 SCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,3,4-tetrahydro-2-oxo-4-[[(3-[2-(trifluoromethyl)-1H-indol-3-yl]methyl)amino]-3-oxo-1-propen-1-yl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 940378-25-1 SCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-3H-pyrrolo[2,3-c]quinol-2-ylmethyl]-N-methyl-3-(5,6,7,8-tetrahydro-3-nc-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 940378-26-2 SCAPLUS
CN 2-Propenamide, N-(4-amino-5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-methyl-N-[(1-methyl-3H-indol-2-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 940378-28-4 SCAPLUS
CN 2-Propenamide, N-methyl-N-[5-quinolinylmethyl]-3-[5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl]-, hydrochloride (1:2), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 940378-52-5 SCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-5-oxoquatphylenyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-3-[(3-[4-morpholinyl]ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 940378-54-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-ylmethyl]-3-[1,2,3,4-tetrahydro-3-[(3-[4-morpholinyl]propyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 940378-60-5 SCAPLUS

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 940378-61-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 940378-62-7 SCAPLUS
CN 2-Propenamide, N-(methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-2,8-naphthyridin-3-yl)- (CA INDEX NAME)



RN 940378-63-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-(2,3,4,5-tetrahydro-4-methyl-5-oxo-1H-pyrido[3,2-e]-1,4-diazepin-7-yl)- (CA INDEX NAME)



RN 940378-64-9 SCAPLUS
CN 2-Propenamide, N-[(3,4-dihydro-3-oxonaphthylenyl)methyl]-N-methyl-3-(2,3,4,5-tetrahydro-4-methyl-5-oxo-1H-pyrido[3,2-e]-1,4-diazepin-7-yl)-

L31 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● HCl

RN 940378-52-5 SCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-5-oxoquatphylenyl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-3-[(3-[4-morpholinyl]ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

● HCl

RN 940378-54-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-ylmethyl]-3-[1,2,3,4-tetrahydro-3-[(3-[4-morpholinyl]propyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Double bond geometry as shown.

● HCl

RN 940378-60-5 SCAPLUS

L33 ANSWER 3 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)



RN 940378-65-0 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-ylmethyl]-3-[1,2,3,4-tetrahydro-3-[(3-[4-morpholinyl]ethyl]-2-oxopyrido[2,3-d]pyrimidin-6-yl]- (CA INDEX NAME)



RN 940378-66-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-1H-indol-2-ylmethyl]-3-(5,6,7,8-tetrahydro-7-oxo-2,8-naphthyridin-3-yl)- (CA INDEX NAME)



IT **338629-81-1P**
RL: BPH (Biochemical process), PREP (Preparation)
(preparation of 1,8-naphthyridine antiotic agents and preparation of intermediate fmol inhibitor)
RN 315033-31-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **740378-27-0P**, (E)-N-[(3-Methyl-1H-indol-2-yl)methyl]-N-methyl-3-(6-[1]benzothiophen-2-ylmethyl-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-2-propenamide **740378-83-8P**, (E)-[4-[[(Methyl](3-methylbenzo[b]thiophen-2-yl)methyl]carbamoyl]vinyl]-2-





```
L31  ANSWER 3 OF 11  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     oxo-1,4-dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]ethanoic acid ethyl ester
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; compns. comprising multiple antibiotic agents and prepn.
        of heterocycle FabI inhibitor)
RN   768378-27-4  ZCAPLUS
CN   2-Propenamide, 3-[6-[(diphenylmethylene)amino]-5,6,7,8-tetrahydro-7-oxo-
     1,8-naphthyridin-3-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-, (2E)-
      (CA INDEX NAME)

Double bond geometry as shown.
```

```
RN   768378-53-6  ZCAPLUS
CN   Pyrido[2,3-d]pyrimidine-3(2H)-acetic acid,
     1,4-dihydro-6-[(1E)-3-[methyl[(3-methylbenzo[b]thien-2-yl)methyl]amino]-3-
     oxo-1-propen-1-yl]-2-oxo-, ethyl ester, sodium salt (1:1)  (CA INDEX NAME)

Double bond geometry as shown.
```

```
OSC.G   3     THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L31  ANSWER 4 OF 11  ZCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2004:143116  ZCAPLUS
DN   140:181461
TI   Preparation of 5,6-fused 3,4-dihydro-2-pyrimidinones, in particular
     5,6-benzo-1,4-dihydro-2-pyrimidinones and
     1,4-dihydro-2H-pyrido[3,4-d]pyrimidin-2-ones, as matrix metalloproteinase
     (MMP) inhibitors, in particular MMP-13 inhibitors
IN   Nahra, Joe; O'Brien, Patrick Michael; Ortwine, Daniel Fred
PA   Warner-Lambert Company Llc, USA
SO   PCT Int. Appl., 194 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE         APPLICATION NO.         DATE
     ---------------     ----   --------     --------------------    --------
PI   WO--2004014869       A2    20040219     2003WO-IB0003534        20030804 <--
     WO--2004014869       A3    20040617
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU--2003250475       A1    20040225     2003AU-000250475        20030804 <--
     US-20040043986       A1    20040304     2003US-000634716        20030805 <--
PRAI 2002US-00403250P     P     20020813  <--
     2003WO-IB0003534     W     20030804  <--
OS   MARPAT 140:181461
GI
```

I

II

```
AB   Title compds. I [wherein R1 = independently (un)substituted
     hetero/cycloalkylenyl, hetero/bicycloalkylenyl, phenylalkylenyl,
     naphthylalkylenyl, hetero(bi)arylalkylenyl, Ph, naphthyl, hetero(bi)aryl,
     R2 = independently H, alkyl, phenylalkylenyl, naphthylalkylenyl,
     hetero(bi)arylalkylenyl, phenyl(oxy/thioxy/sulfinyl/sulfonyl)alkylenyl, B,
     C, D, E = independently CR5 and derivs., N; A = C:O, CH2; R4, R5 =
     independently H, Me, OMe, vinyl, OH, CF3, CN, C(:O)H, C(:O)Me, CH(:NOH),
     NH2, etc.; or R4BA = 3,4,5,6-tetrahydropyridinyl; Q = OC(:O), CH2CO and
     derivs., OCNH and derivs., NH2CO and derivs., NH2SO and derivs.,
     trans-(H)C:C(H), cis-(H)C:C(H), pyrrolidinyl-2-one, etc.; and their
     pharmaceutical acceptable salts] were prepared as matrix metalloproteinase
     (MMP) inhibitors, in particular potent MMP-13 inhibitors (no data).  1
     Synthetic example, 38 claimed compds., 6 biol. methods and 18 formulation
```

```
L31  ANSWER 4 OF 11  ZCAPLUS  COPYRIGHT 2009 ACS on STN     (Continued)
     examples are given.  For example, I was prepd., in 5 steps, by amidation
     of 5-iodo-2-methylaminobenzoic acid with NH3, redn. with BH3-THF,
     cyclization with CDI in THF, N-alkylation of the
     1-methyl-1H-quinazolin-2-one intermediate, followed by Pd-cross coupling
     with 3-phenyl-1-propyne.  I and/or their formulations are useful for
     treating heart disease, multiple sclerosis, osteo- and rheumatoid
     arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac
     insufficiency, inflammatory bowel disease, heart failure, age-related
     macular degeneration, chronic obstructive pulmonary disease, asthma,
     periodontal diseases, psoriasis, atherosclerosis, and osteoporosis (no
     data).
IT   660436-94-2P, 4-[[6-[(4-Methoxybenzylcarbamoyl)methyl]-2-oxo-1,4-
     dihydro-2H-pyrido[2,3-d]pyrimidin-3-yl]methyl]benzoic acid
     660436-95-3P, 1-Methyl-3-(4-methylsulfanylbenzyl)-2-oxo-1,2,3,4-
     tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acid
     N-[(pyridin-3-yl)methyl]amide  660436-96-4P,
     3-[(4-Isopropylbenzyl)methyl]-2-oxo-1,2,3,4-tetrahydropyrido[2,3-
     d]pyrimidine-6-carboxylic acid N-[(pyrimidin-5-yl)methyl]amide
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (MMP-13 inhibitor, preparation of fused dihydropyrimidinones as matrix
        metalloproteinase inhibitors, in particular MMP-13 inhibitors)
RN   660436-94-2  ZCAPLUS
CN   Benzoic acid, 4-[[1,4-dihydro-6-[2-[[(4-methoxyphenyl)methyl]amino]-2-
     oxoethyl]-2-oxopyrido[2,3-d]pyrimidin-3(2H)-yl]methyl]-  (CA INDEX NAME)
```

```
RN   660436-95-3  ZCAPLUS
CN   Pyrido[2,3-d]pyrimidine-6-carboxamide,
     1,2,3,4-tetrahydro-1-methyl-3-[[4-(methylthio)phenyl]methyl]-2-oxo-N-(3-
     pyridinylmethyl)-  (CA INDEX NAME)
```

```
RN   660436-96-4  ZCAPLUS
CN   Pyrido[2,3-d]pyrimidine-6-carboxamide,
     1,2,3,4-tetrahydro-3-[2-[4-(1-methylethyl)phenyl]ethyl]-2-oxo-N-(5-
     pyrimidinylmethyl)-  (CA INDEX NAME)
```

```
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L31  ANSWER 5 OF 11  ZCAPLUS  COPYRIGHT 2009 ACS on STN
AN   2003:855749  ZCAPLUS
DN   139:384948
TI   Preparation of N-(heteroaryl)methylacrylamides as Fab I inhibitors
IN   Burgess, Walter J.; Jakas, Dalia; Huffman, William F.; Miller, William H.;
     Newlander, Kenneth A.; Seefeld, Mark A.; Uzinskas, Irene N.
PA   Affinium Pharmaceuticals, Inc., Can.
SO   PCT Int. Appl., 128 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE         APPLICATION NO.         DATE
     ---------------     ----   --------     --------------------    --------
PI   WO--2003088897       A2    20031030     2002WO-US0010332        20020403 <--
     WO--2003088897       A3    20050609
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GW, GQ, GW, ML, MR, NE, SN, TD, TG
     CA-----2444597       A1    20021006     2002CA-002444597        20020403 <--
     AU--2002367773       A1    20031103     2002AU-000367773        20020403 <--
     JP--2005519984       T     20050707     2003JP-000585650        20020403 <--
     EP-----1560584       A2    20050810     2002EP-000807262        20020403 <--
     EP-----1560584       B1    20090114
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     AT------420640       T     20090115     2002AT-000807262        20020403 <--
     ES-----2320984       T3    20090601     2002ES-000807262        20020403 <--
     US-20040147580       A1    20040729     2003US-000474315        20031006 <--
     US-----7049310       B2    20060523
     US-20060116394       A1    20060601     2005US-000284660        20051122 <--
     US-----7250424       B2    20070731
     US-20090221699       A1    20090903     2007US-000767967        20070625 <--
PRAI 2001US-00282225P     P     20010406  <--
     2002WO-US0010332     W     20020403  <--
     2003US-000474315     A3    20031006  <--
     2005US-000284660     A3    20051122
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 139:364946
GI
```

I

II

```
AB   Title compds. I [R = (un)substituted aryl, heteroaryl; R1, R4 = H, alkyl,
     R2 = H, alkyl, cycloalkyl, R3 = (un)substituted pyridinyl, naphthyridinyl,
     azaindolyl, pyridoazepinyl, pyridodiazepinyl; R5 = H, alkyl, CH2] were
     prepared for use as Fab I inhibitors, useful in the treatment of bacterial
     infections (no data).  Thus, 2-methylindole-3-carboxaldehyde was
     reductively aminated to give 2-methyl-3-methylaminomethylindole which was
```

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
acylated with acryloyl chloride and treated with 2-amino-5-bromopyrimidine to give the amide II.
IT **338029-51-1P**
RL: BCP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-(heteroaryl)methylarylamides as Fab I inhibitors)
RN 338029-51-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-[(3-methyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **620174-26-2P**
RL: BCP (Byproduct); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(heteroaryl)methylarylamides as Fab I inhibitors)
RN 620174-26-2 SCAPLUS
CN 2-Propenamide, 3-[4-[(Cyclopropylmethyl)amino]-3,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl]-N-methyl-N-[(3-methyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT	**498307-21-1P**	**620174-10-7P**	**620174-11-8P**
	620174-25-1P	**620174-26-2P**	**620174-27-3P**
	620174-33-9P	**620174-40-8P**	**620174-41-9P**
	620174-42-0P	**620174-43-1P**	**620174-44-2P**
	620174-45-3P	**620174-46-4P**	**620174-48-6P**
	620174-47-5P	**620174-49-7P**	**620174-73-0P**
	620174-74-1P	**620174-77-4P**	**620174-79-6P**
	620174-80-2P	**620174-81-3P**	**620174-83-5P**
	620174-84-6P	**620174-85-7P**	**620174-87-9P**
	620178-50-0P	**620174-51-1P**	**620174-52-2P**
	620178-53-3P	**620178-54-4P**	**620178-55-5P**
	620178-56-6P	**620178-57-7P**	**620178-58-8P**
	620178-59-9P	**620178-12-4P**	**620178-35-1P**
	620178-36-2P	**620178-37-3P**	**620178-38-4P**
	620178-39-5P	**620178-40-8P**	**620178-41-9P**
	620178-34-0P	**620178-28-4P**	**620178-31-8P**
	620178-45-0P	**620178-43-1P**	**620178-44-2P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(heteroaryl)methylarylamides as Fab I inhibitors)
RN 498307-21-1 SCAPLUS

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620176-24-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-phenylmethyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-28-0 SCAPLUS
CN 2-Propenamide, N-[[1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-93-4 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methylbenzo[b]thien-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 2-Propenamide, N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-N-[(1,2,3,4-tetrahydro-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-10-7 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-1H-indol-3-yl)methyl]-3-(3,5,7,8-tetrahydro-4-methyl-5-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-11-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(3,5,7,8-tetrahydro-3-methyl-2-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-23-4 SCAPLUS
CN 2-Propenamide, N-[(3E)-indol-3-ylmethyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 620174-40-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-41-9 SCAPLUS
CN 2-Propenamide, N-[(2,3-dihydro-1H-pyrrolo[1,2-a]indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620174-42-0 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 620174-43-1 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 31 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 623175-16-9 SCAPLUS
CN 2-Propenamide, N-[(6-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-15-9 SCAPLUS
CN 2-Propenamide, N-[(5-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-43-3 SCAPLUS
CN 2-Propenamide, N-[(7-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 31 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 623176-72-6 SCAPLUS
CN 2-Propenamide, N-[(2-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-77-1 SCAPLUS
CN 2-Propenamide, N-[(3-chloro-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-79-3 SCAPLUS
CN 2-Propenamide, N-[(3-cyano-1-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-77-9 SCAPLUS
CN 2-Propenamide, N-[(3-methyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 31 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 623176-45-5 SCAPLUS
CN 2-Propenamide, N-[(7-chloro-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-67-6 SCAPLUS
CN 2-Propenamide, N,5-dimethyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-49-8 SCAPLUS
CN 2-Butynamide, N-methyl-N-[(3-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (9Z)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 31 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 623176-78-4 SCAPLUS
CN 2-Propenamide, N-[(3-cyano-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 623176-80-7 SCAPLUS
CN 2-Propenamide, N-[(1-ethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 626174-88-2 SCAPLUS
CN 2-Propenamide, N-[(2-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626174-91-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-(3-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 626174-93-8 SCAPLUS
CN 2-Propenamide, N-[(6-fluoro-5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-84-9 ZCAPLUS
CN 2-Propenamide, N-(2-benzofuranylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-98-3 ZCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628176-99-4 ZCAPLUS
CN 2-Propenamide, N-[(6-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-53-3 ZCAPLUS
CN 2-Propenamide, N-[(1,5-dimethyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-54-4 ZCAPLUS
CN 2-Propenamide, N-[(7-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-55-5 ZCAPLUS
CN 2-Propenamide, N-[(7-hydroxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.





RN 628179-60-2 ZCAPLUS
CN 2-Propenamide, N-[1,7-dimethyl-1H-indol-3-yl]methyl-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-61-3 ZCAPLUS
CN 2-Propenamide, N-[1,4-dimethyl-1H-indol-3-yl]methyl-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-62-4 ZCAPLUS
CN 2-Propenamide, N-[1,4-dimethyl-1H-indol-3-yl]methyl-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 628179-56-6 ZCAPLUS
CN 2-Propenamide, N-[(4-chloro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-57-7 ZCAPLUS
CN 2-Propenamide, N-[(4-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-58-8 ZCAPLUS
CN 2-Propenamide, N-[(5-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 628179-10-2 ZCAPLUS
CN 2-Propenamide, N-[(6-methoxy-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-15-1 SCAPLUS
CN 2-Propenamide, N-[(4,1-dimethyl-1H-indeno-3-ylmethyl)-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-20-8 SCAPLUS
CN 2-Propenamide, N-[(4-fluoro-1-methyl-1H-indol-3-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-22-0 SCAPLUS
CN 2-Propenamide, N-methyl-N-(3-quinolinylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-32-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-33-9 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-34-0 SCAPLUS
CN 2-Propenamide, N-ethyl-N-[(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-24-9 SCAPLUS
CN 2-Propenamide, N-methyl-N-(1-naphthalenylmethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-26-2 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-1H-indol-3-ylmethyl-3-(1,2,3,4-tetrahydro-3-[2-methoxyethyl]-3-oxopyrido[2,3-d]pyrimidin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-28-4 SCAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2,3,4-tetrahydro-6-[(2E)-3-[methyl[(1-methyl-1H-indol-3-yl)methyl]amino]-3-oxo-1-propen-1-yl]-2-oxo-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 620175-38-4 SCAPLUS
CN 2-Propenamide, N-[3-benzofuranylmethyl-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 620175-30-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 620175-40-8 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(2-methyl-3-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 620175-43-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[1-(1-methyl-1H-indol-3-yl)ethyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 5 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 401179-44-3 SCAPLUS
CN 3-Propenamide, N-methyl-N-(1-(1-methyl-1H-indol-3-yl)ethyl)-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-2-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

R7 = H, alkyl, aryl, aryl, heteroaryl, etc.; n = 1-8; X1 = alkyl; A = (un)satn., 5- or 6-membered monocyclic ring(s) from 0 to 4 heteroatoms selected from O, S, and N; B = aryl, heteroaryl, etc.; Y = CH2, O, NH, CF2, CHF, CHCF3, etc.; R3 = H, alkyl, alkenyl, aralkyl, etc.) were prepd. Over 220 synthetic examples were provided. For instance, di-Me 6-aminobicyclohexane was treated with benzylisocyanate and heated to 98-102° overnight to give Me 6-(benzylaminocarbonylamino)-1,2,3,4-tetrahydronaphthalene-4-carboxylate which was hydrolyzed (dioxane/aq. LiOH, reflux) to give the carboxylic acid. This intermediate was coupled with benzylamine to afford II. Selected examples of I had IC50 = 2.5h - 0.5Ti uM for MMP13 and IC50 > 100 uM for MMP1, MMP2, MMP3, MMP7, MMP9, MMP10 and MMP14; II had IC50 = 8.193 uM for MMP13. These cpds. were useful for the treatment of osteoarthritis and rheumatoid arthritis.

IT **449210-00-8P**, 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449210-03-1P**, 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine-6-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449210-07-5P**, 6-[(4-(4-Methoxyphenyl)carbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,2-d]pyrimidin-3-yl]methyl benzoic acid **449210-11-1P**
449210-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP13 inhibitor; preparation of quinazolines as specific inhibitors of type-13 matrix metalloproteases)

RN 449210-00-8 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo- (CA INDEX NAME)

RN 449210-03-1 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (CA INDEX NAME)

RN 449210-07-5 SCAPLUS
CN 6-Quinolinecarboxylic acid, 3-[[6-[[(4-methoxyphenyl)amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,2-d]pyrimidin-3(2H)-yl]methyl]- (CA INDEX NAME)



L31 ANSWER 7 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 449210-11-1 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-13-2 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



IT **449210-09-7P** **449210-10-9P**, Methyl 4-[[6-(4-Methoxyphenylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,2-d]pyrimidin-3-yl]methyl]benzoate
RL: PAC (Reactant); SPN (Synthetic preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines as specific inhibitors of type-13 matrix metalloproteases)

RN 449210-09-7 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)

RN 449210-10-0 SCAPLUS
CN Benzoic acid, 4-[[1,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,2-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

L31 ANSWER 4 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:637660 SCAPLUS
DN 137:185561
TI Preparation of quinazolines as specific inhibitors of type-13 matrix metalloproteases
IN Andrianjara, Charles; Chantel-Arroyo, Nicole; Goehlitzer, Bernard; Hamann, Lawrence G.; Ortwine, Daniel Fred; Wahl, William Chester; Pham, Sy; Austin, Catherine Frost; Wilcox, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2002064572	A1	20020822	WO2002-EP1501279	20020211 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, GM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2438222	AA	20020822	CA2002-2438222	20020211 <--
AU 2002225570	A1	20020826	AU2002-225570	20020211 <--
EP 1368334	A1	20031210	EP2002-700723137	20020211 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EE 200300369	A	20040116	EE2003-200300369	20030731 <--
NO 2003003344	A	20030924	NO2003-3344	20030731 <--
JP 2004523546	T	20040805	JP2002-563964505	20020211 <--
CN 1537185	A	20041013	CN2002-808958216	20020211 <--
BR 2002007369	A	20050315	BR2002-7369	20020211 <--
ZA 2003006378	A	20040804	ZA2003-6378	20030813 <--
IS 6910378	A	20030813	IS2003-6910378	20030813 <--
IN 2003006508	A	20041106	IN2003-DN06508	20030814 <--
NO 2003005383	A	20031013	NO2003-5383	20031211 <--
MX 2003008901	A	20040210	MX2003-8901	20031013 <--
KR 2003007944	A	20030924	KR2003-7010469	20030813 <--
PRAI EP1995-200694619	P	19951214 <--		
WO 1996-EP5611	A	19961212 <--		
OS CASREACT 137:185561; MARPAT 137:185561				
GI				

AB Title compds. I [R1 = H, amino, alkyl, alkenyl, alkynyl, alkylamino, aryl, heterocycle, etc.; W = O, S, =N-R', R' = alkyl, H, OH, OR, NH2, NHR, NR2, etc.; Y = O, S, NR; R-alkyl, 2 = O, S, NR7,

L31 ANSWER 8 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 449210-15-4 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)

RN 449210-12-3 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)

IT **449210-08-6P**, Methyl 6-[(6-(4-Methoxyphenylcarbamoyl)-1-methyl-2,4-dioxo-1,4-dihydro-2H-pyrido[3,2-d]pyrimidin-3-yl]methylnicotinate
RL: PAC (Reactant); SPN (Synthetic preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines as specific inhibitors of type-13 matrix metalloproteases)

RN 449210-08-6 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)

RN 449210-16-5 SCAPLUS
CN Benzoic acid, 4-[[6-[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,2-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

L31 ANSWER 6 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:437472 SCAPLUS
DN 137:201351
TI Preparation of substituted tetrahydrofuro acid derivatives, multicyclic pyridinediones and analogs thereof as matrix metalloproteinase inhibitors
IN Ambrosius, Charles; Ortwine, Daniel Fred; Markovsky, Alexander Gregory; Rook, William Howard
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 378 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2002064580	A2	20020822	2002WO-EP00914?	20020213 <--
WO-2002064580	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA------2437841	A1	20020822	2002CA-2437841?	20020213 <--
AU------2002228302	A1	20020828	2002AU-2002228302	20020213 <--
US-2003078276	A1	20030424	2002US-0065078??	20020213 <--
EP------1363875	A2	20031119	2002EP-0907381??	20020213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR-2002007864	A	20040309	2002BR-0007864	20020213 <--
JP-2004520874	T	20040909	2002JP-0565678??	20020213 <--
MX-2003007150	A	20050725	2003MX-0007150	20030813 <--
ZA-2003006317	A	20040812	2003ZA-0006317	20030813 <--
PRAI 2001US-0268521P	P	20010213		
2002US-0065078	A3	20020213	<--	
2002WO-EP00914?	W	20020213	<--	

GI



AB Title compds., I [R1 and R2 together may form a substituted aromatic ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R3a, R3, or R4 = alkyl, arylalkyl, etc.; Y = C, N, Y = O, N with provision when Y is N it forms a 5-membered heterocycle with R3 and II [R5, R6 = arylalkylamine, heterocyclylalcoy, etc.; R7 = H, NHR, NO2,

L31 ANSWER 7 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
etc.], are prepd. and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepd. in five steps via cyclocondensation of 2-(benzyloxycarbonylamino)-3-(4-methoxyphenyl)propionic acid reaction with hydroxylidine synthase to form an in situ intermediate that was reacted with pivaloacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylcinnolinmate. III was demonstrated to inhibit MMP13 with an IC50 value (in μM) of 0.0130. I contain a metal binding group (MBG) which is capable of forming multidentate a hydrogenic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrogenic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the MBG is within 3.5 Å of the catalytic zinc, the hydrogen acceptors bond resp. with Thr245, Tyr247 and Met 253, the first hydrogenic group locates within the S1' channel of MMP-13 and the second hydrogenic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating osteoarthritis, rheumatoid arthritis, cancer, multiple sclerosis, multiple sclerosis, atherosclerosis, and osteoporosis.

IT **449210-58-7P** **449210-60-2P**
RL: RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, cyclocondensation and pharmaceutical activity of substituted tetrahydrofuro acid derivs., multicyclic pyridinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449210-58-7 SCAPLUS
CN Pyrrolo[1,2-d]pyrimidine-4-carboxamide, 1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)



RN 449210-60-2 SCAPLUS
CN Benzoic acid, 4-[[3,4-dihydro-6-[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,2-d]pyrimidin-3(2H)-yl]methyl]-, methyl ester (CA INDEX NAME)



IT **449210-00-8P** **449210-03-1P** **449210-07-5P**
449210-11-1P **449210-12-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted tetrahydrofuro acid derivs., multicyclic pyridinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449210-00-8 SCAPLUS
CN Pyrrolo[1,2-d]pyrimidine-4-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,4-tetrahydro-1,3-dimethyl-2,4-dioxo- (CA INDEX NAME)



L31 ANSWER 7 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 449210-03-1 SCAPLUS
CN 1H-Pyrrolo[1,2-d]pyrimidine-4-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxo-3-(phenylmethyl)- (CA INDEX NAME)

RN 449210-07-5 SCAPLUS
CN Benzoic acid, 4-[[3,4-dihydro-6-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1-methyl-2,4-dioxopyrido[3,2-d]pyrimidin-3(2H)-yl]methyl]- (CA INDEX NAME)



RN 449210-11-1 SCAPLUS
CN Pyrido[3,2-d]pyrimidine-6-carboxamide, 3-[[4-(phenoxymethyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)

RN 449210-12-2 SCAPLUS
CN Pyrrolo[2,3-d]pyrimidin-6-carboxamide, 3-[(4-fluorophenyl)methyl]-1,2,3,4-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-2,4-dioxo- (CA INDEX NAME)

L31 ANSWER 1 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L31 ANSWER 6 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:243945 SCAPLUS
DN 134:311196
TI Preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors
IN Miller, William H.; Newlander, Kenneth A.; Seefeld, Mark A.; Minthorn, Emily A.; Sherrill, Walter E., Jr.; Jakes, Sofia E.
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 149 pp.
CODEN PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2001027163	A1	20010413	2000WO-US027864	20001006 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA------2367814	AA	20010413	2001CA-2367814	20001006 <--
	EP------1226138	A1	20020731	2000EP-0969695	20001006 <--
	EP------1226138	B1	20041229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR------2000014670	A	20020702	2000BR-0014670	20001006 <--
	NZ------2003133	A	20030328	2003NZ-0003133	20001006 <--
	NZ------2003312	A	20040128		
	JP------2003511449	T	20030325	2001JP-0053321	20001006 <--
	AU------2001011	A	20010417	2001AU-0011	20001006 <--
	AU------773216	B2	20040520	2000AU-80017167	20001006 <--
	AI------285421	T	20050115	2000AI-0009964095	20001006 <--
	CN------1179860	C	20040428	2000CN-808813909	20001006 <--
	ES------2231275	T3	20050516	2000ES-0969695855	20001006 <--
	AT------312825	T	20051215	2000AT-0969695855	20001006 <--
	TW------I244529	B	20051201	2000TW-089119838	20001006 <--
	IN------184859	A	20030621	2000IN-CH01183	20001006 <--
	IN------200200396	A	20050318	2002IN-MN00003D6	20020318 <--
	US------6464819	B1	20061015	2001US-0820997055	20010410 <--
	ZA------2002002631	A	20030320	2002ZA-0002002631	20020404 <--
	MX------2002003438	A	20020806	2002MX-0003438	20020405 <--
	US------2002167	A1	20061227		
	PH------2001778	B1	20040611	2001PH-0807044596	20020806 <--
	US-20060229810	A1	20061116	2006US-0820997027	20061220 <--
	US------7057125	B2	20060607		
	US-20081159423	A1	20080515	2007US-0807739578	20070718 <--
	US------7319743	B2	20080108		
PRAI	1999US-0158487P	P	19991008 <--		
	2000WO-US027864	W	20001006 <--		
	2002ZA-0002002631	A1	20020403 <--		
	2006US-0820997027	A3	20061220 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LAND DISPLAY FORMAT
OS MARPAT 134:311196
GI



L31 ANSWER 8 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB The title compds. [I; R = (un)substituted 2-indolyl, 3-quinolyl, 1-naphthyl, etc.; R2 = H, alkyl, cycloalkyl; R3 = (un)substituted 3-pyridyl, Ph, 3-pyrimidinyl, etc.; R4 = H, alkyl; R5 = CH2 or N, alkyl (depending on double or single bond attached)] which are Fab I inhibitors and are useful in the treatment of bacterial infections, were prepared E.g., a multi-step synthesis of (E)-3-(3-pyridyl)-N-[(1-methyl-2-(2-(methylsulfonyl)-1H-indol-3-yl)methyl]-2-propenamide, was given; in the presence of EDC, NOBt and Et3N in DMF afforded 83% (E)-II. The compds. I showed 2.05-100 uM in E. coli Fab1 enzyme inhibition assay.

IT **338028-23-2P**
338028-24-3P
RN 338028-23-2 SCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT **338028-15-9P** **338028-20-8P** **338029-28-2P**
338029-32-6P **338031-31-1P** **338029-34-8P**
338029-36-0P **338031-33-3P**
FA DAC (Biological activity or effector, except adverse); RST (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heteroarylmethyl acrylamides as Fab I inhibitors)
RN 338028-15-9 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(3,3,4,4-tetrahydro-8-methyl-2-oxo-pyrido[3,2-b]pyrazin-6-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 338028-20-8 SCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L31 ANSWER 9 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 338028-23-2 SCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 338029-32-6 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 338029-34-8 SCAPLUS
CN 2-Propenamide, N-[(1,3-dimethyl-1H-indol-2-yl)methyl]-N-methyl-3-(5,6,7,8-tetrahydro-7-oxo-3,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

RN 338029-36-0 SCAPLUS
CN 1,8-Naphthyridine-3-propenamide, 5,6,7,8-tetrahydro-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-7-oxo- (CA INDEX NAME)

L31 ANSWER 8 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 334209-90-8 SCAPLUS
CN 1-Propanamine, N-[(3,4-dimethyl-3H-indol-2-yl)methyl]-N-methyl-2-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (S)- (CA INDEX NAME)

Double bond geometry as shown.

RN 331229-82-1 SCAPLUS
CN 2-Propenamide, N-methyl-N-[(3-methylbenzo[b]thien-2-yl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

GAC/G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 9 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L31 ANSWER 9 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN
AN 1987:169977 SCAPLUS
DN 107:169977
ORGREF 107:9779a
TI Synthesis and properties of amides of 1-benzyl-3-methyl- and 1-butyl-3-phenyl-1-methyl-4-oxo-2-thioxo-(2,4,4a(cis)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylic acids
AU Sladowska, H.; Zawirska, H.
CS Inst. Farmakol. Chemioter., Warsaw, Pol.
SO Farmaco, Edizione Scientifica (1986), 41(12), 914-43
CODEN: FRMSAC; ISSN: 0430-0920
DT Journal
LA English
GI



AB Pyridopyrimidinecarboxamides I and II (R1 = Me2, MeCH2CH2CH2, PhCH2CH2, cyclohexylmethyl, tetrahydrofurfuryl, 1-pyrrolidinyl, piperidono, morpholino, R2 = NH2, MeNHCOCH2, PhCH2NH, cyclohexylamino, 1-pyrrolidinyl, piperidino, morpholino, R3 = PhCH2, Bu; R4 = PhCH2, Bu; R5 = H, Me, Ph) were prepared, and they showed anticonvulsant activity.
TI **105633-25-6P 105633-30-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anticonvulsant activity of)
RN 105633-25-6 SCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-3,7-dimethyl-4-oxo-N,1-bis(phenylmethyl)-2-thioxo- (CA INDEX NAME)



RN 105633-30-3 SCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-3,7-dimethyl-2,4-dioxo-N,1-bis(phenylmethyl)- (CA INDEX NAME)



GAC/G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L31 ANSWER 8 OF 11 SCAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:470677 SCAPLUS
DN 131:228422
TI Replacement of the quinoline system in 3-phenyl-4-quinolinecarbonamide NK-3 receptor antagonists
AU Giardina, G. A. M.; Farina, W.; Concagnani, S.; Cerri, A.; Cuzzolaro, E.; Raveglia, L. F.; Grugni, M.; Hay, D. W. P.; Lattanzi, M. A.; Maga, P.; Saroglia, L. F.; Rigolio, F.; Sarau, H. M.; Schmidt, D. B.; Zenoni, G.; Farina, C.
CS Department of Medicinal Chemistry, SmithKline Beecham S.p.A., Milan, 20051, Italy
SO Farmaco (1999), 54(6), 364-374
CODEN: FRMCEM; ISSN: 0014-827X
PB Elsevier Science S.A.
DT Journal
LA English
GI CASREACT 131:228422

AB Results from a medicinal chemical approach aimed at replacing the quinoline ring system in the potent and selective human neurokinin-3 (NK-3) receptor antagonists (R)-(+)-N-MeOCH2, R1; R1 = Cl, X2 = H, (R)-(+)-N-MeOCH2, Z1 = Cl, Z2 = H) and (R)-(+)-N-Et, Z1 = Cl, Z2 = H) are discussed. The text gives NK-3 receptor binding inhibitory potencies for a series of quinoline isosteres. It is suggested that both the basic nitrogen and the quinoline nitrogen are crucial determinants for optimal binding affinity to the NK-3 receptor. Some novel compds. I (R = MeOCH2, Z1 = Z2 = Cl), R = MeOCH2, Z1 = Z2 = H) and III (R1R2 = McCH2CH2N, CH2CH2CH2CH2) maintained part of the binding affinity to the receptor and compound II, featuring the naphthalene ring system, appeared to be suitable for further modification. The ability of the 2-Me group to induce a perpendicular orientation between the 3 and 4, conferring on the ring an overall electron-deficiency similar to that of the quinoline.
IT **244093-39-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PREP (Preparation); RACT (Reactant or reagent); SPN (Synthetic preparation); BIOL (Biological study)
(preparation, binding affinity and structure-activity relationship of NK-3 receptor antagonists)
RN 244093-39-4 SCAPLUS
CN Pyrido[3,4-d]pyrimidine-5-carboxamide, 1,2,3,4-tetrahydro-4,4-dioxo-7-phenyl-N-(1-phenylpropyl)- (CA INDEX NAME)



GAC/G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 11 OF 11 ICAPLUS COPYRIGHT 2009 ACS on STN
AN 1984(41267 ICAPLUS
DN 101:31197
ORED 101:31197a,31198a
TI Synthesis and properties of 2,3,4,8-tetrahydro-2,4-dioxopyrido[2,3-d]pyrimidines (5-deazaflavins) and their bio-compounds
AU Nishigaki, Nobuyuki; Suga, Kazuo; Tomeba, Kazuo
CS Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, 862, Japan
SO Chemical & Pharmaceutical Bulletin (1984), 32(5), 1899-918
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OI For diagram(s), see printed CA Issue.
AB 8H pyrido[2,3-d]pyrimidine-4-carboxylates I (R = Me, Et, octyl, Ph, 4-MeC6H4, 4-ClC6H4; R1 = Me, Ph and their bio-compds. II (n = 4, 8, 10, 12) were synthesized by condensation of methylureils III with 2-aminonicotinic acid esters. The latter reaction involves a novel rearrangement of a substituent of the 3-position onto the 4-substituent to give the pyrido[2,3-d]pyrimidines IV and their bio-compds. V. The mechanism of the rearrangement was discussed.
IT **92978-17-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 92978-17-1 ICAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carboxamide, 1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-7-phenyl-N-(phenylmethyl)- (CA INDEX NAME)

GAZ-C 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

```
=> d his

     (FILE 'HOME' ENTERED AT 15:21:23 ON 21 OCT 2009)

     FILE 'REGISTRY' ENTERED AT 15:21:48 ON 21 OCT 2009
                ACT J747B/A
                ___________
L1  (    394386)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC5 OR NCNC3-NC5
L2  (      8932)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (NC5-NC6 OR NC5-NCNC4
L3       403278 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (L1 OR L2)
                ___________

     FILE 'STNGUIDE' ENTERED AT 15:24:58 ON 21 OCT 2009

     FILE 'REGISTRY' ENTERED AT 15:27:08 ON 21 OCT 2009
L4                STR
L5             50 L4 SAM SUB=L3
L6          12143 L4 FULL SUB=L3
                  SAV TEM J747C1/A L6
L7                STR L4
L8             50 L7 SAM SUB=L6
L9           1594 L7 FULL SUB=L6
                  SAV TEM J747C1N/A L9

     FILE 'ZCAPLUS' ENTERED AT 15:40:10 ON 21 OCT 2009
L10             1 US20060183908 /PN
L11               TRA L10 1- RN :      478 TERMS

     FILE 'REGISTRY' ENTERED AT 15:40:25 ON 21 OCT 2009
L12           478 SEA L11
L13           130 L12 AND L9
L14          1464 L9 NOT L13
L15               STR L7
L16            50 L15 SAM SUB=L9
L17           932 L15 FULL SUB=L9
                  SAV TEM J747C1N2/A L17
L18           128 L17 AND L12
L19           804 L17 NOT L18

     FILE 'ZCAPLUS' ENTERED AT 15:45:38 ON 21 OCT 2009
L20             4 L18
L21            31 L19
L22            21 L21 AND (PRD<20031205 OR AD<=20031205 OR PD<=20031205)
L23            10 L21 NOT L22

     FILE 'REGISTRY' ENTERED AT 15:51:52 ON 21 OCT 2009
L24           136 E1-136
L25           158 E1-158
L26            75 L24 NOT L25
L27            11 L25 AND (C25H26N404S OR C17H16N4O4 OR C24H22N4O2S OR C28H33N5O3
L28             5 L25 AND (C25H24N4O5 OR C26H24N4O6 OR C23H20N4O3 OR C24H27N5O3)
L29            16 L27-28

     FILE 'ZCAPLUS' ENTERED AT 17:47:08 ON 21 OCT 2009
L30            11 L29
L31            11 L30 AND L22

=>
```